<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS207222</article-id><article-id pub-id-type="doi">10.1101/2025.07.09.663930</article-id><article-id pub-id-type="archive">PPR1050146</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The selective amyloid-driven failure of cholinergic medial septal neurons in aging mice perturbs REM sleep, cognition and emotion, and broadcasts amyloid to other brain regions</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nollet</surname><given-names>Mathieu</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="fn" rid="FN1">5</xref></contrib><contrib contrib-type="author"><name><surname>Ba</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Soto</surname><given-names>Berta Anuncibay</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yin</surname><given-names>Chunyu</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lignos</surname><given-names>Leda</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jovic</surname><given-names>Katarina</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vyssotski</surname><given-names>Alexei L.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Yustos</surname><given-names>Raquel</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Franks</surname><given-names>Nicholas P.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="fn" rid="FN1">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wisden</surname><given-names>William</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="fn" rid="FN1">5</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Life Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Imperial College London</institution></institution-wrap>, <postal-code>SW7 2AZ</postal-code>, <country country="GB">UK</country></aff><aff id="A2"><label>2</label>UK Dementia Research Institute, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Imperial College London</institution></institution-wrap>, <postal-code>SW7 2AZ</postal-code>, <country country="GB">UK</country></aff><aff id="A3"><label>3</label>Department of Neonatal Medical Center, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04pge2a40</institution-id><institution>Children’s Hospital of Nanjing Medical University</institution></institution-wrap>, <city>Nanjing</city><postal-code>210000</postal-code>, <country country="CN">China</country></aff><aff id="A4"><label>4</label>Institute of Neuroinformatics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02crff812</institution-id><institution>University of Zurich</institution></institution-wrap> and <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05a28rw58</institution-id><institution>ETH Zurich</institution></institution-wrap>, <city>Zurich</city><postal-code>8057</postal-code>, <country country="CH">Switzerland</country></aff><author-notes><corresp id="CR1">Correspondence and requests for materials should be addressed to Mathieu Nollet, Nicholas P. Franks or William Wisden.</corresp><fn id="FN1"><label>5</label><p id="P1"><email>m.nollet@imperial.ac.uk</email>; <email>n.franks@imperial.ac.uk</email>; <email>w.wisden@imperial.ac.uk</email></p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>15</day><month>07</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>14</day><month>07</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P2">Early degeneration of basal forebrain cholinergic neurons is a key feature of Alzheimer’s disease (AD). Here, we looked genetically at the intersection of amyloid pathology and the cholinergic system. We expressed in mice of both sexes an <italic>App</italic><sup>NL-G-F</sup> allele, harboring familial AD mutations, specifically in cholinergic medial septum (MS) neurons, and compared the phenotype to mice with global <italic>App</italic><sup>NL-G-F</sup> expression. Over the course of 14 months, as mice reached late middle age, targeted expression led to the loss of about one-third of MS cholinergic neurons and widespread amyloid deposition in their terminal fields, especially in the hippocampus and, to a lesser extent, on blood vessels. This selective vulnerability of ageing cholinergic cells to amyloid, markedly reduced REM sleep and caused cognitive and emotional alterations resembling those in mice with the mutation expressed throughout the brain. Mice with global <italic>App</italic><sup>NL-G-F</sup> expression also had a previously unreported selective death of about 20% of their medial septal cholinergic cells. Although the broadcasting of amyloid by medial septal cholinergic cells is a notable feature, and potentially important in human pathology, selective genetic lesioning of about one third of the medial septal cholinergic cells, independently of amyloid, gave the same REM sleep, cognitive and emotional phenotypes. Thus, it is the killing of the cholinergic cells by amyloid, and therefore the missing acetylcholine, and not the secreted/deposited amyloid in the hippocampus and other areas that is the critical feature. These findings underscore the interest in revitalizing the classic cholinergic hypothesis of AD. Restricting pathological amyloid expression to MS cholinergic neurons, so that their health is compromised by amyloid, is sufficient to reproduce many AD-like symptoms, highlighting the critical role of these cells in early AD pathogenesis, REM sleep regulation, emotion and cognition.</p></abstract><kwd-group><kwd>Alzheimer’s disease</kwd><kwd>amyloid</kwd><kwd>medial septum</kwd><kwd>basal forebrain</kwd><kwd>acetylcholine</kwd><kwd>REM sleep</kwd><kwd>EEG</kwd><kwd>theta</kwd><kwd>memory</kwd><kwd>anxiety</kwd></kwd-group></article-meta></front><body><p id="P3">Acetylcholine (ACh) is a neuromodulator that supports arousal and cognition, synthetized through the choline acetyltransferase (ChAT) enzyme, and activating both metabotropic (muscarinic) and ionotropic (nicotinic) receptors<sup><xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R7">7</xref></sup>. During wakefulness, but also during rapid eye movement sleep (REMS), ACh is released widely into the forebrain from key groups of neurons, the cholinergic basal forebrain (BF), which include, among other nuclei, the medial septum (MS)<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R8">8</xref></sup>. Known for nearly half a century, and confirmed numerous times, the selective degeneration of BF-cholinergic neurons is a notable early feature of Alzheimer’s disease (AD)<sup><xref ref-type="bibr" rid="R9">9</xref>–<xref ref-type="bibr" rid="R22">22</xref></sup>, emerging before entorhinal cortex atrophy<sup><xref ref-type="bibr" rid="R23">23</xref></sup>. It was postulated that this early decline of ACh neurons in humans causes the mild cognitive impairment at the start of AD<sup><xref ref-type="bibr" rid="R10">10</xref></sup>. Cholinergic esterase inhibitors significantly delay the decline of cognition for (some) patients<sup><xref ref-type="bibr" rid="R24">24</xref></sup>, but do not stop the disease progressing<sup><xref ref-type="bibr" rid="R16">16</xref></sup>. For these reasons, according to some commentators, interest in the cholinergic system and AD has languished<sup><xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R17">17</xref></sup>. Instead, the fundamental nature of the AD disease(s) is conceived as proteinopathies, combined with inflammation, with age the biggest risk factor<sup><xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R26">26</xref></sup>.</p><p id="P4">In humans, BF-cholinergic neurons are especially susceptible to amyloid-β (Aβ) toxicity, irrespective of the AD subtype, and BF atrophy correlates with neocortical Aβ burden<sup><xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R27">27</xref>–<xref ref-type="bibr" rid="R29">29</xref></sup>. Thus, it is worth examining how much of the disease symptoms could be accounted for by cholinergic deficits. The MS contains a mixture of ACh, GABA and glutamate neurons which all project to the hippocampus and other areas<sup><xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R21">21</xref>,<xref ref-type="bibr" rid="R30">30</xref>–<xref ref-type="bibr" rid="R33">33</xref></sup>. Aβ peptide injection into the MS of rats disrupts neuronal activity, hippocampal long-term potentiation, theta rhythm and cognition<sup><xref ref-type="bibr" rid="R34">34</xref>,<xref ref-type="bibr" rid="R35">35</xref></sup>. To test if and how selective amyloid pathology influences MS cholinergic (MS<sup>ChAT</sup>) cells, we expressed the synthetic <italic>App</italic><sup>NL-G-F</sup> allele, which comprises a combination of familial AD mutations<sup><xref ref-type="bibr" rid="R36">36</xref></sup>, selectively in mouse MS<sup>ChAT</sup> neurons, and over 14 months, compared the phenotype in mice where the <italic>App</italic><sup>NL-G-F</sup> allele is expressed brain-wide. We found that inducing pathology specifically in the small population of MS<sup>ChAT</sup> neurons generates highly similar phenotypes (<italic>inter alia</italic>, altered cognition and emotional processing, as well as selective REMS deficits) to those of the <italic>App</italic><sup>NL-G-F</sup> <italic>knock-in</italic> mouse<sup><xref ref-type="bibr" rid="R36">36</xref>,<xref ref-type="bibr" rid="R37">37</xref></sup>, where the allele is expressed in multiple cell types. Thus, the integrity of the cholinergic cells underpins a large part of <italic>App</italic><sup>NL-G-F</sup> model’s phenotypic features.</p><sec id="S1" sec-type="results"><title>Results</title><sec id="S2"><title>Cholinergic medial septal cells are wake- and REMS-active and primarily send projections to the hippocampus and cortex</title><p id="P5">We first characterized the target of MS<sup>ChAT</sup> cells. By calcium photometry, MS<sup>ChAT</sup> cells were most active in REMS and WAKE, but quiet in NREMS (<italic>AAV-DIO-GCaMP6s</italic> was injected into the MS of <italic>ChAT-Cre</italic> mice; <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1a-b</xref>). Baseline Ca<sup>2+</sup> transients increased during transitions from NREMS to REMS and NREMS to wakefulness. Many axons projecting from MS<sup>ChAT</sup> cells were detected in hippocampal structures (CA areas, dentate gyrus and subiculum), but also in the medial prefrontal cortex (mPFC; prelimbic and cingulate cortices), primary cortices (somatosensory, motor and visual) and entorhinal cortex, as well as in the olfactory bulb, thalamus, hypothalamus, amygdala, and medial habenula (for the tracing, <italic>AAV-DIO-ChR2-EYFP</italic> was injected into the MS of <italic>ChAT-Cre</italic> mice; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figs. 1c-d</xref>).</p></sec><sec id="S3"><title>Selective expression of a pathological <italic>App</italic> allele in cholinergic medial septal neurons generates localized Aβ accumulation and leads to cholinergic neuronal loss</title><p id="P6">Cre recombinase-dependent AAV transgenes that express the familial <italic>App</italic><sup>NL-G-F</sup> mutations was constructed (<xref ref-type="fig" rid="F1">Fig. 1a</xref>). The viruses <italic>AAV-DIO-App</italic><sup>NL-G-F</sup><italic>-P2A-EGFP</italic> or <italic>AAV-DIO-EGFP</italic> (as a control) were injected into the MS of <italic>ChAT-Cre</italic> male and female mice to generate <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> and <italic>MS<sup>ChAT</sup>-GFP</italic> mice that were then allowed to age for 13 to 14 months (<xref ref-type="fig" rid="F1">Fig. 1a</xref>); their phenotypes were then compared in detail with <italic>App</italic><sup>NL-G-F/NL-G-F</sup> global <italic>knock-in</italic> mice that were aged at the same time.</p><p id="P7">For 13- to 14-month-old <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice, immunohistochemical analyses employing the amyloid-specific antibodies D54D2 and 6E10 (<xref ref-type="fig" rid="F1">Fig. 1c</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2a</xref>, respectively) revealed a marked accumulation of Aβ deposits in the MS (<italic>p</italic> &lt; 0.001, <xref ref-type="fig" rid="F1">Fig. 1d</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2b</xref>). This amyloid deposition extended beyond the MS into adjacent structures of the BF cholinergic system, including the vertical (VDB; <italic>p</italic> = 0.0014 and <italic>p</italic> &lt; 0.001 for D54D2 and 6E10 antibodies, respectively) and horizontal (HDB; <italic>p</italic> &lt; 0.001) limbs of the diagonal band of Broca (<xref ref-type="fig" rid="F1">Fig. 1d</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2b</xref>). There was a comparable increase in Aβ deposits, assessed using the D54D2 antibody, in the same BF regions of 13- to 14-month-old <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice (<italic>p</italic> &lt; 0.001 for MS, VDB and HDB; <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 3a-b</xref>).</p><p id="P8">Notably, in comparison to <italic>MS<sup>ChAT</sup>-GFP</italic> controls, 14-month-old <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice had significantly greater Aβ accumulation in regions innervated by MS<sup>ChAT</sup> cells (<xref ref-type="fig" rid="F1">Fig. 1e-f</xref>). This accumulation was particularly prominent in the CA1, CA2 and hilar areas of the hippocampus, with additional amyloid deposits detected in the thalamus, amygdala, mPFC, primary cortical areas, and the hypothalamus (<xref ref-type="fig" rid="F1">Fig. 1e-f</xref>). However, no increase in Aβ burden was observed in the medial habenula, olfactory bulb, or entorhinal cortex, despite their cholinergic innervation by the MS (see above), nor in the caudate-putamen, where no cholinergic input from the MS was previously detected (see Supplementary information). There was also some colocalization of amyloid and laminin-labeled blood vessels in the hippocampus of <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup>and, to a much lesser extent, <italic>MS<sup>ChAT</sup>-GFP</italic> mice that was not observed in the BF (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2c-d</xref>). This suggests that MS<sup>ChAT</sup> cell terminals preferentially innervate hippocampal blood vessels.</p><p id="P9">Both <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> and homozygous <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice exhibited a loss of MS<sup>ChAT</sup> cells relative to their respective controls, with decreases of 30.7% (<italic>p</italic> &lt; 0.001, <xref ref-type="fig" rid="F2">Fig. 2a-b</xref>) and 19.3% (<italic>p</italic> = 0.0012, <xref ref-type="fig" rid="F2">Fig. 2c-d</xref>), respectively. <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice also had fewer ChAT-expressing neurons in the HDB compared with <italic>App<sup>WT</sup></italic> controls (<xref ref-type="fig" rid="F2">Fig. 2c-d</xref>). The MS also contains GABAergic and glutamatergic neurons and synapses<sup><xref ref-type="bibr" rid="R30">30</xref>–<xref ref-type="bibr" rid="R32">32</xref></sup>. Compared to controls, <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice had reduced GAD67 and VGLUT2 immunoreactivity (collective cell bodies and synapses) in the MS, VDB, and HDB (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4c-d and g-h</xref>). No such changes were observed between <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> and <italic>MS<sup>ChAT</sup>-GFP</italic> mice, however (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4a-b and e-f</xref>).</p><p id="P10">Overall, in the <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice, the intrinsic overproduction of amyloid by MS<sup>ChAT</sup> neurons over about a year caused the degeneration of about a third of them, but the resulting amyloid in the MS did not affect the neighboring non-ChAT cells or synapses.</p></sec><sec id="S4"><title>Aβ-induced disruption of the MS-cholinergic system hinders memory and reduces anxiety-like behavior</title><p id="P11">Home-cage locomotor activity, measured 13- to 14-months following AAV injections, was elevated in both the light and dark phases in <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice compared with <italic>MS<sup>ChAT</sup>-GFP</italic> controls (respectively <italic>p</italic> = 0.0287 and <italic>p</italic> = 0.0129; <xref ref-type="fig" rid="F3">Fig. 3a</xref>). Similarly, <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice exhibited increased activity during the dark period relative to <italic>App<sup>WT</sup></italic> controls (<italic>p</italic> = 0.0063; <xref ref-type="fig" rid="F3">Fig. 3a</xref>). Notably, female mice were consistently more active than males across all groups (see Supplementary information). <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice showed no significant difference in corticosterone concentrations throughout the day compared to <italic>MS<sup>ChAT</sup>-GFP</italic> controls, as assessed by ELISA-based quantification of fecal corticosterone metabolites (FCM; <xref ref-type="fig" rid="F3">Fig. 3b</xref>). By contrast, App <italic>knock-in</italic> mice displayed elevated baseline FCM levels relative to their <italic>App<sup>WT</sup></italic> counterparts (<italic>p</italic> = 0.0038; <xref ref-type="fig" rid="F3">Fig. 3b</xref>). In all types of mice, females consistently exhibited higher baseline levels of FCM than males (see Supplementary information).</p><p id="P12">Behavioral testing was performed 13- to 14-months following AAV injections. Short-term working memory was assessed using the Y-maze paradigm (<xref ref-type="fig" rid="F3">Fig. 3c</xref>). Both <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> and <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice performed significantly worse than their corresponding controls <italic>MS<sup>ChAT</sup>-GFP</italic> and <italic>App<sup>WT</sup></italic> (respectively <italic>p</italic> &lt; 0.001 and <italic>p</italic> = 0.002), indicating impaired spatial working memory. In the novel object recognition task (NORT; <xref ref-type="fig" rid="F3">Fig. 3d</xref>), <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice had no preference for the novel object as opposed to the <italic>MS<sup>ChAT</sup>-GFP</italic> group (<italic>p</italic> &lt; 0.001, <italic>versus</italic> 10 seconds average exploration; <xref ref-type="fig" rid="F3">Fig. 3d</xref>), suggesting impaired non-spatial object memory. Conversely, <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice, like <italic>App<sup>WT</sup></italic> controls, explored the novel object more, indicating intact recognition memory (<italic>p</italic> &lt; 0.001, <italic>versus</italic> 10 seconds average exploration; <xref ref-type="fig" rid="F3">Fig. 3d</xref>). All groups spent comparable amounts of time exploring the two identical objects during the familiarization session of the NORT, confirming equal baseline exploratory behavior (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 5a</xref>).</p><p id="P13">In both the open field and light-dark box tests, <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> and <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice exhibited reduced anxiety-like behavior compared with control groups, with increased time spent in the central zone of the open field (respectively <italic>p</italic> = 0.0031 and <italic>p</italic> = 0.0031; <xref ref-type="fig" rid="F3">Fig. 3e</xref>) and the illuminated chamber of the light-dark box (respectively <italic>p</italic> = 0.0161 and <italic>p</italic> = 0.0146; <xref ref-type="fig" rid="F3">Fig. 3f</xref>).</p><p id="P14">All animals exhibited comparable exploratory behavior across the conducted behavioral assessments (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 6</xref>), with the exception of <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice, which showed in the Y-maze only an increased locomotor activity, as reflected by greater distances traveled and a higher number of arm entries relative to <italic>App<sup>WT</sup></italic> controls (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 6a</xref>).</p></sec><sec id="S5"><title>Aβ deposits restricted to the MS-cholinergic system induce REMS decreases comparable to those in <italic>App</italic><sup>NL-G-F</sup> mice</title><p id="P15">As the mice aged from 4 to 12 months post-AAV injections, we investigated over three time points how amyloid-induced disruption of MS cholinergic neurons affects sleep-wake architecture. In comparison to <italic>MS<sup>ChAT</sup>-GFP</italic> control mice, <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> animals had unchanged amounts of NREMS and WAKE (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figs. 7a and 8a</xref>). However, <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice had fewer (<italic>p</italic> &lt; 0.001), but prolonged (<italic>p</italic> &lt; 0.001), NREMS bouts during the light phase, <italic>i.e</italic>. there was enhanced NREMS consolidation (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 7b-c</xref>). Notably, this same pattern regarding NREMS duration, bout length (<italic>p</italic> = 0.0126), and frequency (<italic>p</italic> = 0.0045) was present in homozygous <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice when compared with <italic>App<sup>WT</sup></italic> controls (Supplementary Figs. 7d-f and 8d-f). Of note, <italic>App</italic><sup>NL-G-F/NL-G-F</sup> animals also displayed an overall increase in WAKE time during the light phase (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 8d</xref>).</p><p id="P16">Contrary to the relatively preserved structure of NREMS and WAKE, marked differences in REMS architecture emerged between <italic>MS<sup>ChAT</sup>-GFP</italic> and <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice. Over the year, the amount of REMS in <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice lessened relative to baseline controls during the light period, so that by 12 months post-AAV injection <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice had clearly less REMS than controls (<italic>p</italic> &lt; 0.001; <xref ref-type="fig" rid="F4">Fig. 4a</xref>). During the dark phase, reduced REMS amount was also observed in <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> animals compared to controls (<italic>p</italic> = 0.0024). Moreover, REMS episodes in these mice became strikingly more consolidated: REMS bouts were longer during the light phase (<italic>p</italic> = 0.0069; <xref ref-type="fig" rid="F4">Fig. 4b</xref>), but there were fewer of them across both light and dark periods (<italic>p</italic> &lt; 0.001; <xref ref-type="fig" rid="F4">Fig. 4c</xref>). During the course of a year, all these REMS changes (less REMS, longer and fewer bouts) were phenocopied in <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice relative to <italic>App<sup>WT</sup></italic> controls (<xref ref-type="fig" rid="F4">Fig. 4d-f</xref>).</p><p id="P17">Spectral analysis of the EEG during REMS in <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice 12 months post-AAV injection revealed, across both light and dark phases, a robust increase in delta oscillations (1-4.4 Hz; light: <italic>p</italic> = 0.0041, dark: <italic>p</italic> = 0.0340) accompanied by a reduction in theta activity (6-9 Hz; light: <italic>p</italic> = 0.0027, dark: <italic>p</italic> = 0.0232) relative to <italic>MS<sup>ChAT</sup>-GFP</italic> controls (<xref ref-type="fig" rid="F4">Fig. 4g</xref>). This spectral shift, indicative of EEG slowing, was also observed during wakefulness in both light (delta: <italic>p</italic> = 0.0194, theta: <italic>p</italic> = 0.0197) and dark (delta: <italic>p</italic> = 0.0063, theta: <italic>p</italic> = 0.0034) periods (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 8g</xref>). In contrast, 12-month-old <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice had unchanged overall EEG power density during REMS and wakefulness compared to <italic>App<sup>WT</sup></italic> counterparts (<xref ref-type="fig" rid="F4">Fig. 4h</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 8h</xref>), one of the few phenotypes where they differed from <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> animals. They, however, had decreased theta rhythms in NREMS during the light period relative to controls (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig.7h</xref>).</p></sec><sec id="S6"><title>Behavioral and sleep alterations of <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice can be primarily attributed to the loss of cholinergic neurons</title><p id="P18">To determine whether the behavioral and sleep phenotypes observed in aged <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice were predominantly attributable to the specific, albeit partial, loss of MS cholinergic neurons or to the deposition of amyloid to other brain areas such as the hippocampus and cortex, we selectively lesioned MS<sup>ChAT</sup> cells independently of amyloid expression. <italic>AAV-DIO-Caspase</italic> was injected into the MS of <italic>ChAT-Cre</italic> male and female mice, thereby generating <italic>MS</italic><sup>Δ<italic>ChAT</italic></sup> animals, which were subsequently aged until 7-8 months post-surgery. Although not anticipated, complete ablation of MS cholinergic neurons in <italic>MS</italic><sup>Δ<italic>ChAT</italic></sup> mice was not achieved. Instead, there was a partial neuronal loss similar in magnitude to that in aged <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> animals, amounting to a 29.5% decrease of MS<sup>ChAT</sup> cells in <italic>MS</italic><sup>Δ<italic>ChAT</italic></sup> mice (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 9a-b</xref>). Similarly to <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice, the number of cholinergic neurons in adjacent BF regions (<italic>i.e</italic>., VDB and HDB) remained unaltered compared with <italic>MS<sup>ChAT</sup>-GFP</italic> controls (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 9a-b</xref>).</p><p id="P19"><italic>MS</italic><sup>Δ<italic>ChAT</italic></sup> and <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice displayed highly similar behavioral and REMS phenotypes (as seen by plotting data from 6-8 months old <italic>MS</italic><sup>Δ<italic>ChAT</italic></sup> mice alongside the data, used in <xref ref-type="fig" rid="F3">Figures 3</xref> to <xref ref-type="fig" rid="F4">4</xref>, from 12-14 months old <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice). Compared to <italic>MS<sup>ChAT</sup>-GFP</italic> controls, <italic>MS</italic><sup>Δ<italic>ChAT</italic></sup> mice made fewer spontaneous alternations in the Y-maze (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 10a</xref>), showed a lack of novelty preference in the NORT (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 10c</xref>); and had reduced anxiety-like behavior in the open-field test (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 10e</xref>). These deficits emerged in the absence of significant differences in overall locomotion or exploratory drive (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figs. 10b, d and f</xref>), suggesting a selective disruption of memory-related and emotional processes.</p><p id="P20"><italic>MS</italic><sup>Δ<italic>ChAT</italic></sup> and <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice also had closely aligned patterns of NREMS and REMS alterations compared with controls. As with <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> animals (12 months after AAV injection), <italic>MS</italic><sup>Δ<italic>ChAT</italic></sup> mice showed a stable total duration of NREMS, but with enhanced consolidation during the light phase, with longer and fewer NREMS bouts (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 12b-c</xref>). REMS patterns were nearly identical between <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> and <italic>MS</italic><sup>Δ<italic>ChA</italic>T</sup> mice, the latter displaying reduced REMS duration and episode number during the light phase, although with no difference observed in the dark period, when compared to <italic>MS<sup>ChAT</sup>-GFP</italic> animals (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 11a and c</xref>). Spectral analyses further highlighted the phenotypic mirroring, with <italic>MS</italic><sup>Δ<italic>ChAT</italic></sup> mice showing elevated delta power, along with decreased theta oscillations, during both REMS and WAKE compared to <italic>MS<sup>ChAT</sup>-GFP</italic> controls (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figs. 11d &amp; 13d</xref>).</p><p id="P21">The phenotypic convergence observed between <italic>MS</italic><sup>Δ<italic>ChAT</italic></sup> and <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice suggests that the primary driver of these phenotypes is the depletion of MS cholinergic neurons, rather than any diffuse effects of broadcasted amyloid from them.</p></sec></sec><sec id="S7" sec-type="discussion"><title>Discussion</title><p id="P22">Remarkably, certain phenotypic traits of ageing <italic>App</italic><sup>NL-G-F</sup> mice can be produced by inducing amyloid pathology solely within MS<sup>ChAT</sup> cells, a discrete group of neurons that send their projections mainly to the hippocampus, with additional connections extending to the medial prefrontal cortex, the primary cortices and entorhinal cortex, as well as in the olfactory bulb, thalamus, hypothalamus, amygdala, and medial habenula. The ACh released by MS<sup>ChAT</sup> cells into these areas is clearly crucial for sustaining neuronal network function. Indeed, ACh is released into the hippocampus during a wide variety of behaviors<sup><xref ref-type="bibr" rid="R7">7</xref></sup>. Our results are threefold: first, a model depicting the selective vulnerability to amyloid of MS<sup>ChAT</sup> cells as they age and the broadcasting of this amyloid produced within them brain-wide, which could be of relevance in human pathology – there are, so far, few models of selective vulnerability in AD; second, how loss of ACh from MS cells degrades REMS generation, the theta rhythm, and the regulation of emotion and cognition; and third, an independent genetic lesioning of MS<sup>ChAT</sup> cells, showing that it is actually the loss of these cells (and thus acetylcholine) that is key for the aberrant sleep and behavior, and not the deposited/released amyloid that originates from these cells.</p><p id="P23">The <italic>App</italic><sup>NL-G-F</sup> allele causes neurodegeneration in knock-in rats and organoids<sup><xref ref-type="bibr" rid="R38">38</xref>,<xref ref-type="bibr" rid="R39">39</xref></sup>. But little cell death has been reported in <italic>App</italic><sup>NL-G-F</sup> homozygous mice<sup><xref ref-type="bibr" rid="R36">36</xref></sup>. We found, however, that a subset (around 20%) of MS<sup>ChAT</sup> cells degenerate in <italic>App</italic><sup>NL-G-F</sup> mice, and that this cell death is reproduced when amyloid is selectively present in MS<sup>ChAT</sup> neurons as they age. Indeed, human cholinergic BF neurons are highly unusual in having high amounts of intraneuronal Aβ-accumulation, perhaps as Aβ oligomers, even in young adults<sup><xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R27">27</xref></sup>. Similarly, in the <italic>5XFAD</italic> mouse line, another model which expresses familial APP mutations, amyloid plaques initially form in the “Papez circuit” (mamillary bodies and medial septal neurons) before appearing in other areas<sup><xref ref-type="bibr" rid="R40">40</xref></sup>. In the <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice, the amyloid within the mouse MS<sup>ChAT</sup> neurons killed about 30% of them during just over a year of expression, yet the local amyloid deposits had no discernable effect on the neighboring glutamate and GABA cells/synapses in the MS. The cell death remained cell-autonomous. Thus, our findings confirm that MS<sup>ChAT</sup> cells are especially susceptible to amyloid toxicity.</p><p id="P24">Intriguingly, the amyloid deposits in <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice are not only confined to the MS but also extend into the hippocampus (especially in the CA pyramidal cell layers and dentate hilus), and other areas innervated by MS<sup>ChAT</sup> cells. Whether the amyloid remains inside the axons of MS<sup>ChAT</sup> neurons or is extracellular, and, if the latter, whether it is released by living MS<sup>ChAT</sup> cells is unclear. For other types of neurons, amyloid and/or APP can be transported along axons to terminals and released from synaptic vesicles during neuronal activity<sup><xref ref-type="bibr" rid="R41">41</xref>–<xref ref-type="bibr" rid="R44">44</xref></sup>. However, the fact that selective ablation of MS<sup>ChAT</sup> cells alone, through targeted caspase expression, produces cognitive, emotional, sleep, and EEG phenotypes nearly identical to those observed in <italic>MS<sup>ChAT</sup>-App</italic><sup>NLG-F</sup> mice suggests that released amyloid in the hippocampus and other projection areas of MS<sup>ChAT</sup> cells would not be responsible <italic>per se</italic> for these sleep/behavioral changes. Rather, it is the loss of ACh that seems critical. But in the human brain, the released amyloid from MS<sup>ChAT</sup> terminals could initiate further pathology in other neurons, possibly with a prion-like mechanism<sup><xref ref-type="bibr" rid="R45">45</xref></sup>.</p><p id="P25">In the hippocampus, a portion of the amyloid originating from the MS<sup>ChAT</sup> axons appears to associate with blood vessels (using laminin staining as a marker for vascular structures). This suggests that the MS<sup>ChAT</sup> cells innervate some blood vessels. Indeed, ACh facilitates cerebral vasodilatation and enhances blood flow<sup><xref ref-type="bibr" rid="R46">46</xref></sup>; on the other hand, reduced vascular reactivity hampers Aβ clearance, potentially contributing to cerebral amyloid angiopathy (CAA)<sup><xref ref-type="bibr" rid="R47">47</xref></sup>. Supporting this, when cholinergic neurons throughout the forebrain in mice were lesioned with mu-saporin, the loss of cholinergic innervation exacerbated neurovascular impairments and CAA progression in the cortex and hippocampus<sup><xref ref-type="bibr" rid="R48">48</xref>,<xref ref-type="bibr" rid="R49">49</xref></sup>.</p><p id="P26">Our study also highlights MS<sup>ChAT</sup> cells as key drivers of REMS, theta rhythmicity, and emotional-cognitive processing. Neurocircuitry that generates REMS is distributed throughout the brain<sup><xref ref-type="bibr" rid="R50">50</xref>–<xref ref-type="bibr" rid="R54">54</xref></sup>. MS<sup>ChAT</sup> neurons are clearly integral components of this network. Similar to cholinergic cells in other basal forebrain nuclei<sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R55">55</xref></sup>, we found that MS<sup>ChAT</sup> cells are specifically active in WAKE and REMS, as also reported by others<sup><xref ref-type="bibr" rid="R56">56</xref></sup>. This pattern of activity aligns with their involvement in theta oscillations during these states, as evidenced by the diminished theta power density in both WAKE and REMS episodes of <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> and <italic>MS</italic><sup>Δ<italic>ChAT</italic></sup> mice, which also experienced significantly less REMS. The REMS deficit in <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice increases with age, presumably reflecting the gradual degeneration of MS<sup>ChAT</sup> cells. Lesions of the MS abolish hippocampal theta<sup><xref ref-type="bibr" rid="R57">57</xref></sup>. Theta activity, including during REMS, is thought to be governed by MS<sup>GABA</sup> cells that project to the hippocampus<sup><xref ref-type="bibr" rid="R31">31</xref>–<xref ref-type="bibr" rid="R33">33</xref></sup>. Opto-inhibiting MS<sup>GABA</sup> cells reduces hippocampal theta<sup><xref ref-type="bibr" rid="R33">33</xref></sup>, but opto-stimulation of MS<sup>ChAT</sup> cells alone failed to elicit hippocampal theta<sup><xref ref-type="bibr" rid="R56">56</xref></sup>. Despite this, our results indicate that MS<sup>ChAT</sup> cells contribute to a component of theta rhythm generation.</p><p id="P27">While other cell-circuit candidates responsible for the reduced REMS phenotype in <italic>App</italic><sup>NL-G-F</sup> mice have been proposed, in particular REMS-generating MCH cells in the lateral hypothalamus and ACh neurons in the pontine brainstem<sup><xref ref-type="bibr" rid="R37">37</xref>,<xref ref-type="bibr" rid="R58">58</xref></sup>, these associations were correlative and did not definitively implicate those cell types in mediating the REMS decline. Unexpectedly, our results reveal that MS<sup>ChAT</sup> neurons also influence the structure of NREMS during the rest (lights-on) period, although the underlying mechanism remains unclear. The fact that, however, in all three mouse models examined—<italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup>, <italic>App</italic><sup>NL-G-F</sup>, and <italic>MS</italic><sup>Δ<italic>ChAT</italic></sup>—the remaining REMS bouts were longer but less frequent, suggests that compensatory adaptation occurred within the sleep circuitry, thus preserving REMS physiological functions.</p><p id="P28">Importantly, the question arises about the consequences of diminished REMS, especially with the latter displaying reduced theta power and elevated delta power. In humans, lower REMS percentages are linked to higher all-cause, cardiovascular, and non-cancer mortality<sup><xref ref-type="bibr" rid="R59">59</xref></sup>. Both REMS and theta rhythms are hypothesized to contribute to enhancing cognition<sup><xref ref-type="bibr" rid="R60">60</xref>–<xref ref-type="bibr" rid="R62">62</xref></sup>, regulating emotions and reducing stress responses<sup><xref ref-type="bibr" rid="R51">51</xref>,<xref ref-type="bibr" rid="R63">63</xref>,<xref ref-type="bibr" rid="R64">64</xref></sup>, processes that are compromised in AD and in individuals living with mild cognitive impairment, as well as in animal models exhibiting widespread Aβ accumulation<sup><xref ref-type="bibr" rid="R37">37</xref>,<xref ref-type="bibr" rid="R65">65</xref>–<xref ref-type="bibr" rid="R78">78</xref></sup>. In humans, EEG slowing during REMS may represent a neurophysiological marker distinguishing older adults with memory impairment from cognitively intact peers<sup><xref ref-type="bibr" rid="R78">78</xref>–<xref ref-type="bibr" rid="R83">83</xref></sup>. Given that <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice have increased EEG delta power during both WAKE and REMS, this may reflect similar pathological alterations seen in humans.</p><p id="P29">Both <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> and <italic>App</italic><sup>NL-G-F</sup> mice exhibited reduced anxiety-like behavior, consistent with previous reports in the 3xTg transgenic model of AD<sup><xref ref-type="bibr" rid="R84">84</xref></sup>. While enhanced hippocampal ACh neurotransmission promotes anxiety in mice<sup><xref ref-type="bibr" rid="R85">85</xref></sup>, selective disruption of the septo-hippocampal cholinergic pathway reduces it<sup><xref ref-type="bibr" rid="R86">86</xref></sup>. In particular, MS<sup>ChAT</sup> projections to the ventral hippocampus (where we observed dense innervation) may regulate anxiety responses, since inhibition of ACh signaling in this region alleviates anxiety under chronic stress conditions<sup><xref ref-type="bibr" rid="R87">87</xref>,<xref ref-type="bibr" rid="R88">88</xref></sup>. MS<sup>ChAT</sup> neurons also enhance spatial and non-spatial working memory<sup><xref ref-type="bibr" rid="R89">89</xref>,<xref ref-type="bibr" rid="R90">90</xref></sup>, and their inputs to the dorsal hippocampus seem more strongly implicated in these processes<sup><xref ref-type="bibr" rid="R88">88</xref></sup>. Inhibition or ablation of MS<sup>ChAT</sup> projections to the dorsal CA2 region of the hippocampus (where we observed prominent amyloid deposition) impairs social cognition in mice<sup><xref ref-type="bibr" rid="R91">91</xref>,<xref ref-type="bibr" rid="R92">92</xref></sup>, which can be restored through the pharmacological increase of cholinergically-driven theta oscillations<sup><xref ref-type="bibr" rid="R91">91</xref></sup>. Collectively, these behavioral observations underscore the central role of MS<sup>ChAT</sup>-hippocampal circuit dysfunction in mediating alterations in risk assessment, working memory, and social cognition. These impairments mirror core symptoms seen in AD patients, including impulsivity, diminished threat perception, short-term memory deficits, and socially inappropriate behavior<sup><xref ref-type="bibr" rid="R93">93</xref></sup>.</p><p id="P30">Overall, our findings imply that disruptions in MS<sup>ChAT</sup> neurons, in the early stages of AD, reduces and slows REMS, alters NREMS architecture, causes EEG theta power to decrease and delta power to increase during wakefulness and REMS, and produces associated cognitive and emotional impairments. As demonstrated by the specific caspase-induced lesions of MS<sup>ChAT</sup> cells, any neurodegenerative insult that damages these cells will likely produce similar cognitive, emotional and sleep phenotypes as excessive amyloid production. Therefore, preserving MS<sup>ChAT</sup> cells integrity in a variety of neurodegenerative diseases could slow decline of patients. Encouragingly, choline supplementation to pregnant <italic>App</italic><sup>NL-G-F</sup> mice reduces learning and memory impairments and brain Aβ deposition in progeny<sup><xref ref-type="bibr" rid="R94">94</xref></sup>; and a year-long administration of an acetylcholinesterase inhibitor protected against prodromal atrophy of MS<sup>ChAT</sup> cells in AD patients<sup><xref ref-type="bibr" rid="R95">95</xref></sup>. This might suggest that keeping MS<sup>ChAT</sup> neurons healthier for longer in patients, or even replacing them, like the approaches being used for dopamine cell loss in Parkinson’s disease, may provide an improved palliative therapy route that could be combined with amyloid-targeting treatments to enhance clinical outcome in AD.</p><p id="P31">This study highlights the central importance of early MS<sup>ChAT</sup> cell loss, and particularly their heightened vulnerability to initial amyloid accumulation, in the prodromal phase of AD. This neuronal loss is intricately linked to early rise of sleep disruptions, most notably in REMS, alongside subtle cognitive impairments and emotional dysregulation. These findings underscore the interest in revitalizing the cholinergic hypothesis of AD<sup><xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R17">17</xref></sup>, and <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice may prove to be a valuable model.</p></sec><sec id="S8" sec-type="methods"><title>Methods</title><p id="P32">All procedures were approved by the Animal Welfare Ethical Review Body at Imperial College London. Experiments were performed in accordance with the UK Home Office Animal Procedures Act (1986).</p></sec><sec id="S9"><title>Mice</title><p id="P33">We used adult <italic>App</italic><sup>NL-G-F</sup> homozygous mice with the Swedish (KM670/671NL), Beyreuther/Iberian (I716F) and Arctic (E22G) <italic>knock-in</italic> mutations in the <italic>APP</italic> gene (these mice were a gift from Takashi Saito, Institute of Brain Science, Nagoya City University Graduate School of Medical Sciences, and Takaomi Saido, RIKEN Centre for Brain Science, Wako, Saitama, Japan)<sup><xref ref-type="bibr" rid="R36">36</xref></sup>. The <italic>ChAT-ires-Cre</italic> mice (<italic>B6;129S6-Chat<sup>tm2(cre)Lowl</sup></italic>/J) were from JAX labs (JAX #031661, a gift of Bradford Lowell - Beth Israel Deaconess Medical Center, Harvard)<sup><xref ref-type="bibr" rid="R96">96</xref></sup>. Animals were maintained under a 12-h light/12-h dark cycle in a controlled environment (21 ± 1 °C; 55 ± 10% relative humidity) with <italic>ad libitum</italic> access to food and water. Environmental enrichment was provided in the form of PVC tunnels and wooden chew blocks. For all mouse strains, males and females were used in all experiments.</p></sec><sec id="S10"><title>AAV constructs and production</title><p id="P34">In the <italic>pAAV-hsyn-DIO-App<sup>NL-G-F</sup>-P2A-EGFP and pAAV-hsyn-DIO-App<sup>NL-G-F</sup>-P2A-mCherry</italic> AAV transgenes, the <italic>APP<sup>NL-G-F</sup>-2A-EGFP</italic> or <italic>APP<sup>NL-G-F</sup>-2A-mCherry</italic> reading frames, flanked by heterologous Cre recombination sites, are under the control of the human synapsin promoter. The transgenes were made as follows. An <italic>App</italic><sup>NL-G-F</sup> reading frame, flanked by <italic>AscI</italic> and <italic>AgeI</italic> sites, was synthesized by Eurofins (Eurofins Genomics UK Limited) and supplied in a pEX-A258 plasmid. The <italic>App</italic><sup>NL-G-F</sup> 2267bp band was gel purified from this plasmid as an <italic>AscI-App<sup>NL-G-F</sup>-AgeI</italic> fragment, and ligated into an <italic>AAV-hsyn-DIO-P2A-EGFP</italic> transgene vector doubly-digested with <italic>AscI</italic> and <italic>AgeI</italic>, to generate <italic>AAV-hsyn-DIO-App<sup>NL-G-F</sup>-P2A-EGFP</italic>. A similar procedure generated the <italic>pAAV-hsyn-DIO-App<sup>NL-G-F</sup>-P2A-mCherry</italic> transgene. The transgenes also contained a woodchuck post-transcriptional regulatory element (WPRE) and polyadenylation sequences. These plasmids and their sequences, <italic>pAAV-hsyn-DIO-App<sup>NL-G-F</sup>-P2A-EGFP and pAAV-hsyn-DIO-App<sup>NL-G-F</sup>-P2A-mCherry</italic>, have been deposited at Addgene.</p><p id="P35">We also used the following <italic>pAAV</italic> transgene plasmids: <italic>pAAV-hSyn-DIO-EGFP</italic> was a gift from Bryan Roth (Addgene plasmid 50457), <italic>pAAV-EF1a-flex-taCasp3-TEVp</italic> was a gift from Nirao Shah<sup><xref ref-type="bibr" rid="R97">97</xref></sup> (Addgene plasmid 45580), <italic>pAAV-DIO-GCaMP6s</italic> transgene was constructed by us and described previously<sup><xref ref-type="bibr" rid="R98">98</xref></sup> (Addgene plasmid 184284), <italic>pAAV-DIO-ChR2-EYFP</italic> was a gift from Karl Deisseroth (Addgene plasmid 20298).</p><p id="P36">The AAVs consisted of a mixed capsid serotype combining AAV1 and AAV2. To generate AAVs, the adenovirus helper plasmid <italic>pFΔ6</italic>, the AAV helper plasmids <italic>pH21</italic> (AAV1) and <italic>pRVI</italic> (AAV2), along with the <italic>pAAV</italic> transgene plasmids, were co-transfected into HEK293 cells. Following this, the resulting AAV particles were purified in-house using heparin columns<sup><xref ref-type="bibr" rid="R99">99</xref></sup>.</p></sec><sec id="S11"><title>Stereotaxic surgery</title><p id="P37">Prior to surgical procedures, mice were group-housed and allowed at least one week to acclimatize to the animal facility. Surgeries were conducted at 11-13 weeks of age, after which mice were individually housed for the duration of the <italic>in vivo</italic> experiments. Mice were randomly assigned to either experimental or control groups. Anesthesia was induced and maintained with 2% isoflurane in oxygen, delivered via inhalation. Preoperative analgesia and anti-inflammatory treatment were administered subcutaneously using buprenorphine (0.1 mg·kg<sup>-1</sup>) and carprofen (5 mg·kg<sup>-1</sup>). Animals were then positioned and secured in a stereotaxic apparatus (Angle Two; Leica Microsystems) for the duration of the surgical procedure. Postoperatively, carprofen was provided in the drinking water (5 mg·kg<sup>-1</sup> per day), and mice were allowed to recover in their home cages for a minimum of 3 weeks prior to further experimentation.</p></sec><sec id="S12"><title>AAV Injections</title><p id="P38">Viral vectors were delivered using a stainless steel 33-gauge internal cannula (13 mm, PST3; Hamilton Company) connected to a 10-μl Hamilton microsyringe. Injections were performed at a rate of 0.1 μl·min<sup>-1</sup>, with the following constructs and volumes: <italic>pAAV-hsyn-DIO-App<sup>NL-G-F</sup>-P2A-EGFP</italic> (1 μl), <italic>pAAV-hSyn-DIO-EGFP</italic> (1 μl), a combination of <italic>pAAV-EF1a-flex-taCasp3-TEVp</italic> and <italic>pAAV-hSyn-DIO-EGFP</italic> (0.5 μl each), <italic>pAAV-DIO-GCaMP6s</italic> (0.5 μl), and <italic>pAAV-DIO-ChR2-EYFP</italic> (1 μl). The cannula was slowly lowered to the target site in the MS (coordinates: 0.05 mm ML, 0.8 mm AP, -4.4 mm DV relative to bregma). Following injection, the cannula was left in place for 5 min before being withdrawn slowly to minimize backflow.</p></sec><sec id="S13"><title>Fiber photometry implantation</title><p id="P39">In mice receiving <italic>AAV-DIO-GCaMP6</italic> injections, a 200-μm diameter, 0.5 NA (numerical aperture) mono-fiber optic cannula (RWD Life Science) was surgically implanted 100 μm above the injection site in the MS and secured with a cured acrylic resin (Simplex Rapid powder and Rapid Liquid, Kemdent). Mice were allowed to recover for 3 weeks prior to photometry recording.</p></sec><sec id="S14"><title>Headstage implantation for EEG/EMG recordings</title><p id="P40">All mice were implanted with two miniature screw electrodes for EEG recording. Electrodes were prepared by soldering ultra flexible PVC lead EEG wires (NUF30-4046BLACK, Cooner Wire) to the screws and positioned at standard locations: frontal cortex (-1.7 mm ML, +1.5 mm AP relative to bregma) and parietal cortex (-1.7 mm ML, +1.0 mm AP relative to lambda). EMG electrodes (stranded stainless-steel wire; AS634, Cooner Wire) were inserted bilaterally into the neck musculature. All wires were soldered to a 7-pin header, which was secured to the skull using a cured acrylic resin (Simplex Rapid powder and Rapid Liquid, Kemdent).</p></sec><sec id="S15"><title>Sleep-wake analysis</title><p id="P41">Continuous EEG and EMG recordings were acquired for a minimum of 48 h using untethered Neurologger 2A devices<sup><xref ref-type="bibr" rid="R100">100</xref></sup>, which were connected to a 7-pin headstage implant. Data were recorded at a sampling rate of 200 Hz with fourfold oversampling. In MATLAB (MathWorks), EEG signals were processed using a high-pass digital filter (highpass function; cutoff frequency: 0.5 Hz, -3 dB), while EMG signals were filtered using a band-pass digital filter (bandpass function; 5-45 Hz, -3 dB).</p></sec><sec id="S16"><title>Sleep scoring</title><p id="P42">For sleep state classification, 24-h EEG/EMG recordings were analyzed, comprising 12-h light and 12-h dark phases. These recordings were collected 3 times at 4-month intervals following AAV injection or from birth in both <italic>App</italic><sup>NL-G-F/NL-G-F</sup> and <italic>App<sup>WT</sup></italic> mice. For <italic>MS</italic><sup>Δ<italic>ChAT</italic></sup> mice, recordings were collected 6 months post-injection. Vigilance states, <italic>i.e</italic>. non-rapid eye movement sleep (NREMS), rapid eye movement sleep (REMS) and wakefulness, were manually scored in 5-s epochs using SleepSign for Animal software (KISSEI COMTEC Co.) by an experienced experimenter blinded to treatment conditions.</p></sec><sec id="S17"><title>EEG power spectral analysis</title><p id="P43">EEG power spectral densities were computed for successive 5-s epochs using the Welch method in MATLAB (pwelch function; frequency range: 1-15 Hz; resolution: 0.2 Hz; non-overlapping Hanning window), a more robust and less noisy variant of fast Fourier transform. Epochs exhibiting EEG artifacts were excluded from spectral analyses. Power spectra were calculated separately for NREMS, REMS, and wakefulness during both light and dark phases. For each epoch, spectral power within each 0.2 Hz EEG frequency bin was normalized to the total spectral power of that epoch, expressing power values as a percentage of the corresponding total EEG power. Delta power (1-4.4 Hz) and theta power (6-9 Hz) were quantified by summing power within the respective frequency bands.</p></sec><sec id="S18"><title>Calcium photometry</title><p id="P44">To assess the spontaneous activity of MS cholinergic neurons across sleep-wake states (NREMS, REMS, and wakefulness), we employed fiber photometry using the genetically encoded calcium indicator GCaMP6s, as previously described<sup><xref ref-type="bibr" rid="R98">98</xref>,<xref ref-type="bibr" rid="R101">101</xref></sup>. Simultaneous EEG/EMG recordings were acquired to accurately determine vigilance states during photometry sessions. Recordings were conducted minimum 3 weeks post-surgery during the light (rest) phase between zeitgeber time (ZT) 0 and ZT6, with each session lasting 3-6 h. Each animal underwent 3 to 4 recording sessions.</p></sec><sec id="S19"><title>Photometry recording</title><p id="P45">A 473-nm diode-pumped solid-state blue laser (ADR-800A, Shanghai Laser &amp; Optics Century Co.) was used to excite GCaMP6s. The excitation light was routed through a single-source fluorescence cube (FMC_GFP_FC, Doric Lenses) <italic>via</italic> an optical fiber patch cord (Ø 200 μm, 0.22 NA, Doric Lenses). Emitted fluorescence passed through the same cube and was transmitted via a multimodal optical patch cord (Ø 200 μm, 0.37 NA, Doric Lenses) connected to the ceramic-implanted fiber optic cannula (Ø 200 μm, 0.37 NA, Doric Lenses) using a split mating sleeve ferrule (Thorlabs). The GCaMP6s emission signal was filtered between 500-550 nm and detected by an amplified photodiode (APD-FC, Doric Lenses). The photodiode output was relayed to a lock-in amplifier (SR810, Stanford Research Systems), which also modulated the laser at 125 Hz. Laser power was maintained at 80 μW at the fiber tip. The demodulated signal was digitized using a CED 1401 Micro Box (Cambridge Electronic Design) and recorded at a sampling rate of 1 kHz using Spike2 software (Cambridge Electronic Design).</p></sec><sec id="S20"><title>Neuronal activity analysis</title><p id="P46">All photometry data were analyzed using MATLAB. Signals were temporally aligned with the EEG/EMG recordings. Analyses focused on 100-s windows enclosing transitions between vigilance states (NREMS to REMS, NREMS to wakefulness and wakefulness to NREMS). The raw fluorescence signal (F) was normalized to a baseline using the formula<sup><xref ref-type="bibr" rid="R98">98</xref></sup>: <disp-formula id="FD1"><mml:math id="M1"><mml:mrow><mml:mtext>Δ</mml:mtext><mml:mi>F</mml:mi><mml:mo>/</mml:mo><mml:mi>F</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>F</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>F</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>F</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p id="P47">In some recordings, an initial transient decay in signal intensity was observed; therefore, only sessions with stable photometry signals following this decay period were included in the final analysis.</p></sec><sec id="S21"><title>Histological analysis</title><sec id="S22"><title>Immunohistochemistry</title><p id="P48">Mice were transcardially perfused with 4% paraformaldehyde (Thermo Scientific) in phosphate-buffered saline (PBS; Sigma). Brains were extracted, post-fixed in 30% sucrose in PBS for cryoprotection, and later coronally sectioned (40 μm thickness) using a HM 450 sliding microtome (Thermo Scientific). Free-floating sections were washed 3 times in PBS (5 min each), followed by epitope retrieval in 0.05% Tween-20 in 10 mM sodium citrate buffer (pH 6.0) at 80-85 °C for 30 min. Sections were then cooled at room temperature for 15 min and washed 3 times in PBS (10 min each). Non-specific binding was blocked by incubating the sections for 1 h in PBS containing 0.2% Triton X-100 and 20% normal donkey or goat serum. Sections were incubated overnight at 4 °C on a shaker with one or two primary antibodies diluted in PBS supplemented with 2% normal serum. The following day, sections were washed 3 times in PBS (10 min each), incubated for 1.5 h at room temperature with the appropriate secondary antibody diluted in PBS with 2% normal serum, and washed again 3 times (10 min each). When two primary antibodies were used, each corresponding secondary antibody incubation was performed sequentially, with intermediate PBS washes (3 times, 10 min each), to prevent cross-reactivity. For triple labeling, a third primary antibody was applied, followed on the subsequent day by the corresponding secondary antibody as described. Nuclear staining was performed by incubating the sections in Hoechst (1:5,000; Invitrogen) for 3 min at room temperature, followed by three washes in PBS (5 min each). The primary antibodies used included chicken anti-GFP (1:1,000; abcam, ab13970), goat anti-ChAT (1:200; Merck, AB144P), rabbit anti-D54D2 (1:500; Cell Signaling Technology, 8243), mouse anti-6E10 (1:1,000; BioLegend, 803001), rabbit anti-laminin (1:350; Merck, L9393), rabbit anti-GAD67 (1:500; Invitrogen, PA5-21397), and guinea pig anti-VGluT2 (1:200; Merck, AB2251-I). Secondary antibodies (1:500; Invitrogen) included Alexa Fluor 488-conjugated donkey anti-chicken (A78948), donkey anti-mouse (A-21202), and goat anti-chicken (A-11039), Alexa Fluor 568-conjugated donkey anti-goat (A-11057), donkey anti-mouse (A10037), and goat anti-guinea pig (A-11075), as well as Alexa Fluor 647-conjugated donkey anti-rabbit (A-31573) and goat anti-rabbit (A-21245). Sections were mounted on glass slides using ProLong Gold antifade mounting medium (Invitrogen) and cover-slipped.</p></sec><sec id="S23"><title>Data analysis and quantification</title><p id="P49">Imaging was performed using a ZEISS Axio Observer inverted widefield fluorescence microscope coupled with the ZEISS ZEN Pro software (Facility for Imaging by Light Microscopy, Imperial College London). Histological analyses were conducted using the Fiji distribution of ImageJ. Core preinstalled functions were employed for unbiased quantification of neuronal counts and stained areas, utilizing automatic thresholding algorithms included in the Fiji package. Co-localization analyses were performed using the BIOP JaCoP plugin, allowing for quantitative assessment of signal overlap between markers.</p></sec></sec><sec id="S24"><title>Behavioral and baseline stress analysis</title><p id="P50">All behavioral assessments were conducted 13-14 months post-surgery or afterbirth, and during the animals’ active (dark) phase under red light, specifically between Zeitgeber Time (ZT) 16 and ZT22. Animal behavior was recorded using an overhead camera and analyzed automatically with the ANY-maze software (Stoelting Co.), except for the light-dark box test, which was conducted using the Zantiks LT automated apparatus (Zantiks). Video tracking enabled precise quantification of locomotion, orientation, activity, and total distance traveled.</p><sec id="S25"><title>Y-maze</title><p id="P51">The Y-maze task was employed to evaluate spontaneous alternation behavior, an index of spatial working memory<sup><xref ref-type="bibr" rid="R102">102</xref></sup>. Each mouse was placed at the center of a Y-shaped maze (arm length: 30 cm, width: 6 cm, wall height: 15 cm), with the orientation of entry arms counterbalanced across subjects. Arm entries and total distance traveled were recorded over a 10-min session. A spontaneous alternation was defined as consecutive entries into three different arms. The percentage of spontaneous alternation was calculated as: <disp-formula id="FD2"><mml:math id="M2"><mml:mrow><mml:mtext>Spontaneous</mml:mtext><mml:mspace width="0.2em"/><mml:mtext>Alternation</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mo>%</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mfrac><mml:mrow><mml:mtext>Number</mml:mtext><mml:mspace width="0.2em"/><mml:mtext>of</mml:mtext><mml:mspace width="0.2em"/><mml:mtext>Alternations</mml:mtext></mml:mrow><mml:mrow><mml:mtext>Total</mml:mtext><mml:mspace width="0.2em"/><mml:mtext>Arm</mml:mtext><mml:mspace width="0.2em"/><mml:mtext>Entries</mml:mtext><mml:mo>−</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mo stretchy="false">)</mml:mo><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math></disp-formula></p></sec><sec id="S26"><title>Novel object recognition task (NORT)</title><p id="P52">To assess non-spatial working memory, the NORT was performed as described previously<sup><xref ref-type="bibr" rid="R103">103</xref></sup>. During the habituation phase, mice were allowed to explore an empty square arena (45 cm × 45 cm, height: 40 cm) for 10 min. This session also served as the open field test for evaluating anxiety-like behavior (see below). Twenty-four hours later, in the familiarization phase, two identical objects were placed 5 cm from the arena walls, and mice were allowed to explore until a total of 20 s of object interaction was reached. This criterion ensured consistent exploration across animals, irrespective of their inherent activity levels. Another 24 hours later, one familiar object was replaced with a novel one, and mice were again allowed to explore both objects until 20 s of cumulative exploration time was reached. Object type and positioning were randomized between animals and experimental groups, and the time to reach the 20 s exploration criterion was recorded.</p></sec><sec id="S27"><title>Open field</title><p id="P53">Anxiety-like behavior was evaluated using the open field paradigm. Mice were placed in the center of a square arena (45 cm × 45 cm, height: 40 cm) and allowed to explore freely for 10 min. The time spent in the central zone, defined as 25% of the total area and considered anxiogenic, were measured, as well as the number of entries into the central zone and the total distance traveled. This session also constituted the initial habituation phase for the NORT (see above).</p></sec><sec id="S28"><title>Light-dark box</title><p id="P54">Bright-light-induced anxiety was assessed using the light-dark box test. The setup included a white bright compartment (23.5 cm × 27 cm, height: 30 cm; ~150 lux illumination from a translucent floor) connected to a dark compartment (11.5 cm × 27 cm, height: 30 cm) via a 5 cm semi-circle opening. The dark compartment was covered with a removable black semi-translucent lid. Mice were introduced into the center of the dark compartment, facing away from the connecting opening, and allowed to explore both compartments for 5 min. Time spent in the illuminated compartment, the number of transitions between compartments and the total distance traveled were recorded.</p></sec><sec id="S29"><title>Home-cage locomotor activity</title><p id="P55">Spontaneous locomotor activity in the home cage was continuously monitored for an average of 6.8 consecutive days using custom-built devices modeled after a previously published protocol<sup><xref ref-type="bibr" rid="R104">104</xref></sup>. Each unit consisted of a passive infrared sensor connected to a customized microcontroller (M0 AdaLogger, Adafruit #2796), housed within a 3D-printed casing containing a lithium-ion battery for wireless operation. Devices were placed in the cage on the wire lid, allowing uninterrupted monitoring of activity (total activity duration per min) without disturbing the animals.</p></sec><sec id="S30"><title>Assessment of stress hormone levels</title><p id="P56">Basal stress levels were assessed via fecal corticosterone metabolite (FCM) concentrations using a commercial ELISA kit (ADI-901-097, Enzo), following a previously described protocol optimized and validated in our laboratory<sup><xref ref-type="bibr" rid="R105">105</xref></sup>. Feces were collected over a 28-h period, divided into five ZT-defined windows: ZT20-ZT0 (final 4 h of dark phase), ZT0-ZT12 (entire light phase), ZT12-ZT16, ZT16-ZT20, and ZT20-ZT0. One week prior to sample collection, animals were habituated to alternating between two uncleaned cages (containing their own scent, enrichment and bedding material), minimizing environmental stress during sampling. At the beginning of the collection period, mice were transferred to the other previously occupied but feces-free cage, and subsequent swaps were performed at each ZT interval. Feces were collected from the previously used cage after each swap and stored at -20 °C until processing. Each sample was homogenized in 5 mL of 95% ethanol per gram of feces, thoroughly ground, and incubated overnight at room temperature. Samples were centrifuged at 3,000 × g for 20 min; the supernatant was collected and centrifuged again at 10,000 × g for 15 min. A 200 μL aliquot of the final supernatant was evaporated to dryness in an open tube under a fume hood. The residue was then reconstituted in 250 μL of assay buffer (provided with the ELISA kit), vortexed, incubated overnight at 4 °C, and stored at -20 °C until analysis. All samples were diluted 1:10 prior to assay and processed in accordance with the manufacturer’s instructions.</p></sec></sec><sec id="S31"><title>Statistics</title><p id="P57">All statistical analyses were conducted using R (R Core Team) in RStudio (Posit). <italic>A priori</italic> power analyses were performed prior to the start of the study using previously collected in-lab data to estimate the required sample size for achieving adequate statistical power (typically α = 0.05 and power ≥ 80%). All datasets satisfied the assumptions necessary for parametric testing, including normality and homoscedasticity. With the exception of photometry recordings and the NORT, which were analyzed using paired and one-sample Student’s <italic>t</italic>-tests respectively, all other data were analyzed using either standard ANOVA (via the lm function in base R) when no random effects were present, or linear mixed-effects models (via the lmer function from the lme4 R package) when accounting for random factors, such as repeated measures from the same subject or anatomical variability across brain section locations in histological analyses. Fixed effects included experimental group, sex, and time (for repeated measures), modeled as interacting categorical variables, as well as brain region in the analysis of 6E10/laminin colocalization staining. <italic>Post hoc</italic> pairwise comparisons were conducted using Holm-Bonferroni correction for multiple testing, implemented through the lsmeans and contrast functions from the emmeans R package. All statistical analyses reported in the main text reflect overall “group” effects, irrespective of other potential fixed effects, and were conducted on pooled male and female data unless otherwise specified, with all values expressed as mean ± standard error of the mean (SEM). Full statistical details are provided in the Supplementary information.</p></sec><sec id="S32"><title>Reporting summary</title><p id="P58">Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Material</label><media xlink:href="EMS207222-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="d2aAcVbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S33"><title>Acknowledgements</title><p>Preparation for this article was supported by the Wellcome Trust (220759/Z/20/Z, to N.P.F. and W.W.); and the UK Dementia Research Institute (award number UK DRI-5004) through UK DRI Ltd, principally funded by the Medical Research Council (W.W., N.P.F.).</p></ack><fn-group><fn fn-type="con" id="FN2"><p id="P59"><bold>Author contributions</bold></p><p id="P60">M.N. performed behavioral experiments, surgeries and AAV injections, EEG and behavioral analysis, histology, all general data analysis and assembled and designed all figures.</p><p id="P61">W.B. performed surgeries and calcium photometry analysis.</p><p id="P62">B.A.S. performed surgeries and helped with histology experiments.</p><p id="P63">C.Y. helped with histology experiments.</p><p id="P64">L.L. helped with stress hormone level analysis.</p><p id="P65">K.J. helped with histology experiments.</p><p id="P66">A.L.V. provided the Neurologger 2A devices.</p><p id="P67">R.Y. performed all molecular biology and AAV transgene construction, AAV production, mouse genotyping.</p><p id="P68">M.N., N.P.F and W.W. conceived and designed the experiments. N.P.F. and W.W. co-supervised the project. M.N., N.P.F. and W.W. co-wrote the paper.</p></fn><fn fn-type="conflict" id="FN3"><p id="P69"><bold>Competing interests</bold></p><p id="P70">The authors declare no competing interests.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ananth</surname><given-names>MR</given-names></name><name><surname>Rajebhosale</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Talmage</surname><given-names>DA</given-names></name><name><surname>Role</surname><given-names>LW</given-names></name></person-group><article-title>Basal forebrain cholinergic signalling: development, connectivity and roles in cognition</article-title><source>Nat Rev Neurosci</source><year>2023</year><volume>24</volume><fpage>233</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/s41583-023-00677-x</pub-id><pub-id pub-id-type="pmcid">PMC10439770</pub-id><pub-id pub-id-type="pmid">36823458</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picciotto</surname><given-names>MR</given-names></name><name><surname>Higley</surname><given-names>MJ</given-names></name><name><surname>Mineur</surname><given-names>YS</given-names></name></person-group><article-title>Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior</article-title><source>Neuron</source><year>2012</year><volume>76</volume><fpage>116</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.08.036</pub-id><pub-id pub-id-type="pmcid">PMC3466476</pub-id><pub-id pub-id-type="pmid">23040810</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Basal forebrain circuit for sleep-wake control</article-title><source>Nat Neurosci</source><year>2015</year><volume>18</volume><fpage>1641</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nn.4143</pub-id><pub-id pub-id-type="pmcid">PMC5776144</pub-id><pub-id pub-id-type="pmid">26457552</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irmak</surname><given-names>SO</given-names></name><name><surname>de Lecea</surname><given-names>L</given-names></name></person-group><article-title>Basal forebrain cholinergic modulation of sleep transitions</article-title><source>Sleep</source><year>2014</year><volume>37</volume><fpage>1941</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.5665/sleep.4246</pub-id><pub-id pub-id-type="pmcid">PMC4548510</pub-id><pub-id pub-id-type="pmid">25325504</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galvin</surname><given-names>VC</given-names></name><name><surname>Arnsten</surname><given-names>AFT</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name></person-group><article-title>Evolution in Neuromodulation-The Differential Roles of Acetylcholine in Higher Order Association vs. Primary Visual Cortices</article-title><source>Front Neural Circuits</source><year>2018</year><volume>12</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.3389/fncir.2018.00067</pub-id><pub-id pub-id-type="pmcid">PMC6121028</pub-id><pub-id pub-id-type="pmid">30210306</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desikan</surname><given-names>S</given-names></name><name><surname>Koser</surname><given-names>DE</given-names></name><name><surname>Neitz</surname><given-names>A</given-names></name><name><surname>Monyer</surname><given-names>H</given-names></name></person-group><article-title>Target selectivity of septal cholinergic neurons in the medial and lateral entorhinal cortex</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><fpage>E2644</fpage><lpage>E2652</lpage><pub-id pub-id-type="doi">10.1073/pnas.1716531115</pub-id><pub-id pub-id-type="pmcid">PMC5856533</pub-id><pub-id pub-id-type="pmid">29487212</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobryakova</surname><given-names>YV</given-names></name><name><surname>Bolshakov</surname><given-names>AP</given-names></name><name><surname>Korotkova</surname><given-names>T</given-names></name><name><surname>Rozov</surname><given-names>AV</given-names></name></person-group><article-title>Acetylcholine in the hippocampus: problems and achievements</article-title><source>Front Neural Circuits</source><year>2025</year><volume>19</volume><elocation-id>1491820</elocation-id><pub-id pub-id-type="doi">10.3389/fncir.2025.1491820</pub-id><pub-id pub-id-type="pmcid">PMC12075383</pub-id><pub-id pub-id-type="pmid">40371058</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Generation of a whole-brain atlas for the cholinergic system and mesoscopic projectome analysis of basal forebrain cholinergic neurons</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><fpage>415</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1073/pnas.1703601115</pub-id><pub-id pub-id-type="pmcid">PMC5777024</pub-id><pub-id pub-id-type="pmid">29259118</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Maloney</surname><given-names>AJ</given-names></name></person-group><article-title>Selective loss of central cholinergic neurons in Alzheimer’s disease</article-title><source>Lancet</source><year>1976</year><volume>2</volume><fpage>1403</fpage><pub-id pub-id-type="pmid">63862</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartus</surname><given-names>RT</given-names></name><name><surname>Dean</surname><given-names>RL</given-names><suffix>3rd</suffix></name><name><surname>Beer</surname><given-names>B</given-names></name><name><surname>Lippa</surname><given-names>AS</given-names></name></person-group><article-title>The cholinergic hypothesis of geriatric memory dysfunction</article-title><source>Science</source><year>1982</year><volume>217</volume><fpage>408</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">7046051</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossor</surname><given-names>MN</given-names></name><etal/></person-group><article-title>A post-mortem study of the cholinergic and GABA systems in senile dementia</article-title><source>Brain</source><year>1982</year><volume>105</volume><fpage>313</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">7082992</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitehouse</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain</article-title><source>Science</source><year>1982</year><volume>215</volume><fpage>1237</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7058341</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geula</surname><given-names>C</given-names></name><etal/></person-group><article-title>Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance</article-title><source>J Neurochem</source><year>2021</year><volume>158</volume><fpage>1394</fpage><lpage>1411</lpage><pub-id pub-id-type="doi">10.1111/jnc.15471</pub-id><pub-id pub-id-type="pmcid">PMC8458251</pub-id><pub-id pub-id-type="pmid">34272732</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aghourian</surname><given-names>M</given-names></name><etal/></person-group><article-title>FEOBV-PET to quantify cortical cholinergic denervation in AD: Relationship to basal forebrain volumetry</article-title><source>J Neuroimaging</source><year>2021</year><volume>31</volume><fpage>1077</fpage><lpage>1081</lpage><pub-id pub-id-type="pmid">34462992</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilimann</surname><given-names>I</given-names></name><etal/></person-group><article-title>Subregional basal forebrain atrophy in Alzheimer’s disease: a multicenter study</article-title><source>J Alzheimers Dis</source><year>2014</year><volume>40</volume><fpage>687</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.3233/JAD-132345</pub-id><pub-id pub-id-type="pmcid">PMC4120953</pub-id><pub-id pub-id-type="pmid">24503619</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>AS</given-names></name><name><surname>Harrison</surname><given-names>TM</given-names></name></person-group><article-title>New perspectives on the basal forebrain cholinergic system in Alzheimer’s disease</article-title><source>Neurosci Biobehav Rev</source><year>2023</year><volume>150</volume><elocation-id>105192</elocation-id><pub-id pub-id-type="doi">10.1016/j.neubiorev.2023.105192</pub-id><pub-id pub-id-type="pmcid">PMC10249144</pub-id><pub-id pub-id-type="pmid">37086935</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampel</surname><given-names>H</given-names></name><etal/></person-group><article-title>Revisiting the Cholinergic Hypothesis in Alzheimer’s Disease: Emerging Evidence from Translational and Clinical Research</article-title><source>J Prev Alzheimers Dis</source><year>2019</year><volume>6</volume><fpage>2</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.14283/jpad.2018.43</pub-id><pub-id pub-id-type="pmcid">PMC12280792</pub-id><pub-id pub-id-type="pmid">30569080</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grothe</surname><given-names>M</given-names></name><etal/></person-group><article-title>Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer’s disease</article-title><source>Cereb Cortex</source><year>2010</year><volume>20</volume><fpage>1685</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhp232</pub-id><pub-id pub-id-type="pmcid">PMC2912653</pub-id><pub-id pub-id-type="pmid">19889714</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>W</given-names></name><etal/></person-group><article-title>Altered multimodal magnetic resonance parameters of basal nucleus of Meynert in Alzheimer’s disease</article-title><source>Ann Clin Transl Neurol</source><year>2020</year><volume>7</volume><fpage>1919</fpage><lpage>1929</lpage><pub-id pub-id-type="doi">10.1002/acn3.51176</pub-id><pub-id pub-id-type="pmcid">PMC7545587</pub-id><pub-id pub-id-type="pmid">32888399</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>TW</given-names></name><etal/></person-group><article-title>Longitudinal Alzheimer’s Degeneration Reflects the Spatial Topography of Cholinergic Basal Forebrain Projections</article-title><source>Cell Rep</source><year>2018</year><volume>24</volume><fpage>38</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.06.001</pub-id><pub-id pub-id-type="pmcid">PMC8840819</pub-id><pub-id pub-id-type="pmid">29972789</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballinger</surname><given-names>EC</given-names></name><name><surname>Ananth</surname><given-names>M</given-names></name><name><surname>Talmage</surname><given-names>DA</given-names></name><name><surname>Role</surname><given-names>LW</given-names></name></person-group><article-title>Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline</article-title><source>Neuron</source><year>2016</year><volume>91</volume><fpage>1199</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2016.09.006</pub-id><pub-id pub-id-type="pmcid">PMC5036520</pub-id><pub-id pub-id-type="pmid">27657448</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taza</surname><given-names>M</given-names></name><name><surname>Schmitz</surname><given-names>TW</given-names></name><name><surname>Spreng</surname><given-names>RN</given-names></name></person-group><article-title>Structural changes to the basal forebrain cholinergic system in the continuum of Alzheimer disease</article-title><source>Handb Clin Neurol</source><year>2025</year><volume>211</volume><fpage>81</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">40340069</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>TW</given-names></name><name><surname>Nathan Spreng</surname><given-names>R</given-names></name><collab>Alzheimer’s Disease Neuroimaging, I</collab></person-group><article-title>Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><elocation-id>13249</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms13249</pub-id><pub-id pub-id-type="pmcid">PMC5097157</pub-id><pub-id pub-id-type="pmid">27811848</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartus</surname><given-names>RT</given-names></name></person-group><article-title>On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis</article-title><source>Exp Neurol</source><year>2000</year><volume>163</volume><fpage>495</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">10833325</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korczyn</surname><given-names>AD</given-names></name><name><surname>Grinberg</surname><given-names>LT</given-names></name></person-group><article-title>Is Alzheimer disease a disease?</article-title><source>Nat Rev Neurol</source><year>2024</year><volume>20</volume><fpage>245</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/s41582-024-00940-4</pub-id><pub-id pub-id-type="pmcid">PMC12077607</pub-id><pub-id pub-id-type="pmid">38424454</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Hallmarks of neurodegenerative diseases</article-title><source>Cell</source><year>2023</year><volume>186</volume><fpage>693</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">36803602</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker-Nigh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Neuronal amyloid-beta accumulation within cholinergic basal forebrain in ageing and Alzheimer’s disease</article-title><source>Brain</source><year>2015</year><volume>138</volume><fpage>1722</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1093/brain/awv024</pub-id><pub-id pub-id-type="pmcid">PMC4542619</pub-id><pub-id pub-id-type="pmid">25732182</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alldred</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Profiling Basal Forebrain Cholinergic Neurons Reveals a Molecular Basis for Vulnerability Within the Ts65Dn Model of Down Syndrome and Alzheimer’s Disease</article-title><source>Mol Neurobiol</source><year>2021</year><volume>58</volume><fpage>5141</fpage><lpage>5162</lpage><pub-id pub-id-type="doi">10.1007/s12035-021-02453-3</pub-id><pub-id pub-id-type="pmcid">PMC8680118</pub-id><pub-id pub-id-type="pmid">34263425</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerbler</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Basal forebrain atrophy correlates with amyloid beta burden in Alzheimer’s disease</article-title><source>Neuroimage Clin</source><year>2015</year><volume>7</volume><fpage>105</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.nicl.2014.11.015</pub-id><pub-id pub-id-type="pmcid">PMC4299972</pub-id><pub-id pub-id-type="pmid">25610772</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>S</given-names></name><etal/></person-group><article-title>Medial septum glutamatergic neurons control wakefulness through a septo-hypothalamic circuit</article-title><source>Curr Biol</source><year>2021</year><volume>31</volume><fpage>1379</fpage><lpage>1392</lpage><elocation-id>e4</elocation-id><pub-id pub-id-type="pmid">33545041</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>A</given-names></name><name><surname>Salib</surname><given-names>M</given-names></name><name><surname>Viney</surname><given-names>TJ</given-names></name><name><surname>Dupret</surname><given-names>D</given-names></name><name><surname>Somogyi</surname><given-names>P</given-names></name></person-group><article-title>Behavior-Dependent Activity and Synaptic Organization of Septo-hippocampal GABAergic Neurons Selectively Targeting the Hippocampal CA3 Area</article-title><source>Neuron</source><year>2017</year><volume>96</volume><fpage>1342</fpage><lpage>1357</lpage><elocation-id>e5</elocation-id><pub-id pub-id-type="doi">10.1016/j.neuron.2017.10.033</pub-id><pub-id pub-id-type="pmcid">PMC5746169</pub-id><pub-id pub-id-type="pmid">29198757</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salib</surname><given-names>M</given-names></name><etal/></person-group><article-title>GABAergic Medial Septal Neurons with Low-Rhythmic Firing Innervating the Dentate Gyrus and Hippocampal Area CA3</article-title><source>J Neurosci</source><year>2019</year><volume>39</volume><fpage>4527</fpage><lpage>4549</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3024-18.2019</pub-id><pub-id pub-id-type="pmcid">PMC6554630</pub-id><pub-id pub-id-type="pmid">30926750</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyce</surname><given-names>R</given-names></name><name><surname>Glasgow</surname><given-names>SD</given-names></name><name><surname>Williams</surname><given-names>S</given-names></name><name><surname>Adamantidis</surname><given-names>A</given-names></name></person-group><article-title>Causal evidence for the role of REM sleep theta rhythm in contextual memory consolidation</article-title><source>Science</source><year>2016</year><volume>352</volume><fpage>812</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">27174984</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colom</surname><given-names>LV</given-names></name><etal/></person-group><article-title>Medial septal beta-amyloid 1-40 injections alter septo-hippocampal anatomy and function</article-title><source>Neurobiol Aging</source><year>2010</year><volume>31</volume><fpage>46</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2008.05.006</pub-id><pub-id pub-id-type="pmcid">PMC2810281</pub-id><pub-id pub-id-type="pmid">18547680</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>MN</given-names></name><etal/></person-group><article-title>Amyloid beta protein injection into medial septum impairs hippocampal long-term potentiation and cognitive behaviors in rats</article-title><source>Sheng Li Xue Bao</source><year>2018</year><volume>70</volume><fpage>217</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">29926062</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>T</given-names></name><etal/></person-group><article-title>Single App knock-in mouse models of Alzheimer’s disease</article-title><source>Nat Neurosci</source><year>2014</year><volume>17</volume><fpage>661</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">24728269</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maezono</surname><given-names>SEB</given-names></name><etal/></person-group><article-title>Progressive Changes in Sleep and Its Relations to Amyloid-beta Distribution and Learning in Single App Knock-In Mice</article-title><source>eNeuro</source><year>2020</year><volume>7</volume><pub-id pub-id-type="doi">10.1523/ENEURO.0093-20.2020</pub-id><pub-id pub-id-type="pmcid">PMC7196722</pub-id><pub-id pub-id-type="pmid">32321771</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>K</given-names></name><etal/></person-group><article-title>An App knock-in rat model for Alzheimer’s disease exhibiting Abeta and tau pathologies, neuronal death and cognitive impairments</article-title><source>Cell Res</source><year>2022</year><volume>32</volume><fpage>157</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1038/s41422-021-00582-x</pub-id><pub-id pub-id-type="pmcid">PMC8807612</pub-id><pub-id pub-id-type="pmid">34789895</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group><article-title>APOE3ch alleviates Abeta and tau pathology and neurodegeneration in the human APP(NL-G-F) cerebral organoid model of Alzheimer’s disease</article-title><source>Cell Res</source><year>2024</year><volume>34</volume><fpage>451</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/s41422-024-00957-w</pub-id><pub-id pub-id-type="pmcid">PMC11143179</pub-id><pub-id pub-id-type="pmid">38609581</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gail Canter</surname><given-names>R</given-names></name><etal/></person-group><article-title>3D mapping reveals network-specific amyloid progression and subcortical susceptibility in mice</article-title><source>Commun Biol</source><year>2019</year><volume>2</volume><fpage>360</fpage><pub-id pub-id-type="doi">10.1038/s42003-019-0599-8</pub-id><pub-id pub-id-type="pmcid">PMC6778135</pub-id><pub-id pub-id-type="pmid">31602409</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cirrito</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo</article-title><source>Neuron</source><year>2005</year><volume>48</volume><fpage>913</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">16364896</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buxbaum</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path</article-title><source>J Neurosci</source><year>1998</year><volume>18</volume><fpage>9629</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.18-23-09629.1998</pub-id><pub-id pub-id-type="pmcid">PMC6793291</pub-id><pub-id pub-id-type="pmid">9822724</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nitsch</surname><given-names>RM</given-names></name><name><surname>Farber</surname><given-names>SA</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><name><surname>Wurtman</surname><given-names>RJ</given-names></name></person-group><article-title>Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices</article-title><source>Proc Natl Acad Sci U S A</source><year>1993</year><volume>90</volume><fpage>5191</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.11.5191</pub-id><pub-id pub-id-type="pmcid">PMC46681</pub-id><pub-id pub-id-type="pmid">8506366</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groemer</surname><given-names>TW</given-names></name><etal/></person-group><article-title>Amyloid precursor protein is trafficked and secreted via synaptic vesicles</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><elocation-id>e18754</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0018754</pub-id><pub-id pub-id-type="pmcid">PMC3083403</pub-id><pub-id pub-id-type="pmid">21556148</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlson</surname><given-names>GA</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><article-title>How an Infection of Sheep Revealed Prion Mechanisms in Alzheimer’s Disease and Other Neurodegenerative Disorders</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><pub-id pub-id-type="doi">10.3390/ijms22094861</pub-id><pub-id pub-id-type="pmcid">PMC8125442</pub-id><pub-id pub-id-type="pmid">34064393</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>14096</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1073/pnas.251542998</pub-id><pub-id pub-id-type="pmcid">PMC61174</pub-id><pub-id pub-id-type="pmid">11707605</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways</article-title><source>Nat Rev Neurol</source><year>2020</year><volume>16</volume><fpage>30</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1038/s41582-019-0281-2</pub-id><pub-id pub-id-type="pmcid">PMC7268202</pub-id><pub-id pub-id-type="pmid">31827267</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nizari</surname><given-names>S</given-names></name><name><surname>Wells</surname><given-names>JA</given-names></name><name><surname>Carare</surname><given-names>RO</given-names></name><name><surname>Romero</surname><given-names>IA</given-names></name><name><surname>Hawkes</surname><given-names>CA</given-names></name></person-group><article-title>Loss of cholinergic innervation differentially affects eNOS-mediated blood flow, drainage of Abeta and cerebral amyloid angiopathy in the cortex and hippocampus of adult mice</article-title><source>Acta Neuropathol Commun</source><year>2021</year><volume>9</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s40478-020-01108-z</pub-id><pub-id pub-id-type="pmcid">PMC7791879</pub-id><pub-id pub-id-type="pmid">33413694</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nizari</surname><given-names>S</given-names></name><name><surname>Carare</surname><given-names>RO</given-names></name><name><surname>Romero</surname><given-names>IA</given-names></name><name><surname>Hawkes</surname><given-names>CA</given-names></name></person-group><article-title>3D Reconstruction of the Neurovascular Unit Reveals Differential Loss of Cholinergic Innervation in the Cortex and Hippocampus of the Adult Mouse Brain</article-title><source>Front Aging Neurosci</source><year>2019</year><volume>11</volume><fpage>172</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2019.00172</pub-id><pub-id pub-id-type="pmcid">PMC6620643</pub-id><pub-id pub-id-type="pmid">31333445</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luppi</surname><given-names>PH</given-names></name><etal/></person-group><article-title>Neuronal network controlling REM sleep</article-title><source>J Sleep Res</source><year>2025</year><volume>34</volume><elocation-id>e14266</elocation-id><pub-id pub-id-type="pmid">38972672</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ba</surname><given-names>W</given-names></name><etal/></person-group><article-title>A REM-active basal ganglia circuit that regulates anxiety</article-title><source>Curr Biol</source><year>2024</year><volume>34</volume><fpage>3301</fpage><lpage>3314</lpage><elocation-id>e4</elocation-id><pub-id pub-id-type="pmid">38944034</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miracca</surname><given-names>G</given-names></name><etal/></person-group><article-title>NMDA Receptors in the Lateral Preoptic Hypothalamus Are Essential for Sustaining NREM and REM Sleep</article-title><source>J Neurosci</source><year>2022</year><volume>42</volume><fpage>5389</fpage><lpage>5409</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0350-21.2022</pub-id><pub-id pub-id-type="pmcid">PMC7613025</pub-id><pub-id pub-id-type="pmid">35649726</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashiwagi</surname><given-names>M</given-names></name><etal/></person-group><article-title>A pontine-medullary loop crucial for REM sleep and its deficit in Parkinson’s disease</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>6272</fpage><lpage>6289</lpage><elocation-id>e21</elocation-id><pub-id pub-id-type="pmid">39303715</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamantidis</surname><given-names>AR</given-names></name><name><surname>de Lecea</surname><given-names>L</given-names></name></person-group><article-title>Sleep and the hypothalamus</article-title><source>Science</source><year>2023</year><volume>382</volume><fpage>405</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">37883555</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MG</given-names></name><name><surname>Hassani</surname><given-names>OK</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>BE</given-names></name></person-group><article-title>Cholinergic basal forebrain neurons burst with theta during waking and paradoxical sleep</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><fpage>4365</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0178-05.2005</pub-id><pub-id pub-id-type="pmcid">PMC6725118</pub-id><pub-id pub-id-type="pmid">15858062</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X</given-names></name><etal/></person-group><article-title>The Firing of Theta State-Related Septal Cholinergic Neurons Disrupt Hippocampal Ripple Oscillations via Muscarinic Receptors</article-title><source>J Neurosci</source><year>2020</year><volume>40</volume><fpage>3591</fpage><lpage>3603</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1568-19.2020</pub-id><pub-id pub-id-type="pmcid">PMC7189758</pub-id><pub-id pub-id-type="pmid">32265261</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawlins</surname><given-names>JN</given-names></name><name><surname>Feldon</surname><given-names>J</given-names></name><name><surname>Gray</surname><given-names>JA</given-names></name></person-group><article-title>Septo-hippocampal connections and the hippocampal theta rhythm</article-title><source>Exp Brain Res</source><year>1979</year><volume>37</volume><fpage>49</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">385334</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calafate</surname><given-names>S</given-names></name><etal/></person-group><article-title>Early alterations in the MCH system link aberrant neuronal activity and sleep disturbances in a mouse model of Alzheimer’s disease</article-title><source>Nat Neurosci</source><year>2023</year><volume>26</volume><fpage>1021</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1038/s41593-023-01325-4</pub-id><pub-id pub-id-type="pmcid">PMC10244178</pub-id><pub-id pub-id-type="pmid">37188873</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leary</surname><given-names>EB</given-names></name><etal/></person-group><article-title>Association of Rapid Eye Movement Sleep With Mortality in Middle-aged and Older Adults</article-title><source>JAMA Neurol</source><year>2020</year><volume>77</volume><fpage>1241</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2020.2108</pub-id><pub-id pub-id-type="pmcid">PMC7550971</pub-id><pub-id pub-id-type="pmid">32628261</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Della Monica</surname><given-names>C</given-names></name><name><surname>Johnsen</surname><given-names>S</given-names></name><name><surname>Atzori</surname><given-names>G</given-names></name><name><surname>Groeger</surname><given-names>JA</given-names></name><name><surname>Dijk</surname><given-names>DJ</given-names></name></person-group><article-title>Rapid Eye Movement Sleep, Sleep Continuity and Slow Wave Sleep as Predictors of Cognition, Mood, and Subjective Sleep Quality in Healthy Men and Women, Aged 20-84 Years</article-title><source>Front Psychiatry</source><year>2018</year><volume>9</volume><fpage>255</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2018.00255</pub-id><pub-id pub-id-type="pmcid">PMC6024010</pub-id><pub-id pub-id-type="pmid">29988413</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djonlagic</surname><given-names>I</given-names></name><etal/></person-group><article-title>Macro and micro sleep architecture and cognitive performance in older adults</article-title><source>Nat Hum Behav</source><year>2021</year><volume>5</volume><fpage>123</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1038/s41562-020-00964-y</pub-id><pub-id pub-id-type="pmcid">PMC9881675</pub-id><pub-id pub-id-type="pmid">33199858</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scullin</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Rapid eye movement sleep mediates age-related decline in prospective memory consolidation</article-title><source>Sleep 42</source><year>2019</year><pub-id pub-id-type="doi">10.1093/sleep/zsz055</pub-id><pub-id pub-id-type="pmcid">PMC6559169</pub-id><pub-id pub-id-type="pmid">30860593</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nollet</surname><given-names>M</given-names></name><etal/></person-group><article-title>REM sleep’s unique associations with corticosterone regulation, apoptotic pathways, and behavior in chronic stress in mice</article-title><source>Proc Natl Acad Sci U S A</source><year>2019</year><volume>116</volume><fpage>2733</fpage><lpage>2742</lpage><pub-id pub-id-type="doi">10.1073/pnas.1816456116</pub-id><pub-id pub-id-type="pmcid">PMC6377491</pub-id><pub-id pub-id-type="pmid">30683720</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Nollet</surname><given-names>M</given-names></name><name><surname>Franks</surname><given-names>NP</given-names></name><name><surname>Wisden</surname><given-names>W</given-names></name></person-group><article-title>Sleep and the recovery from stress</article-title><source>Neuron</source><year>2025</year><pub-id pub-id-type="pmid">40409251</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chetty</surname><given-names>CA</given-names></name><etal/></person-group><article-title>EEG biomarkers in Alzheimer’s and prodromal Alzheimer’s: a comprehensive analysis of spectral and connectivity features</article-title><source>Alzheimers Res Ther</source><year>2024</year><volume>16</volume><fpage>236</fpage><pub-id pub-id-type="doi">10.1186/s13195-024-01582-w</pub-id><pub-id pub-id-type="pmcid">PMC11515355</pub-id><pub-id pub-id-type="pmid">39449097</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zawislak-Fornagiel</surname><given-names>K</given-names></name><etal/></person-group><article-title>Quantitative EEG Spectral and Connectivity Analysis for Cognitive Decline in Amnestic Mild Cognitive Impairment</article-title><source>J Alzheimers Dis</source><year>2024</year><volume>97</volume><fpage>1235</fpage><lpage>1247</lpage><pub-id pub-id-type="pmid">38217593</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulver</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Mapping sleep’s oscillatory events as a biomarker of Alzheimer’s disease</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><fpage>301</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1002/alz.13420</pub-id><pub-id pub-id-type="pmcid">PMC10840635</pub-id><pub-id pub-id-type="pmid">37610059</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olgun</surname><given-names>Y</given-names></name><name><surname>Aksoy Poyraz</surname><given-names>C</given-names></name><name><surname>Bozluolcay</surname><given-names>M</given-names></name><name><surname>Poyraz</surname><given-names>BC</given-names></name></person-group><article-title>Quantitative EEG in the Differential Diagnosis of Dementia Subtypes</article-title><source>J Geriatr Psychiatry Neurol</source><year>2024</year><volume>37</volume><fpage>368</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">38217438</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meghdadi</surname><given-names>AH</given-names></name><etal/></person-group><article-title>EEG and ERP biosignatures of mild cognitive impairment for longitudinal monitoring of early cognitive decline in Alzheimer’s disease</article-title><source>PLoS One</source><year>2024</year><volume>19</volume><elocation-id>e0308137</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0308137</pub-id><pub-id pub-id-type="pmcid">PMC11309464</pub-id><pub-id pub-id-type="pmid">39116138</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>BA</given-names></name><name><surname>Strittmatter</surname><given-names>SM</given-names></name><name><surname>Nygaard</surname><given-names>HB</given-names></name></person-group><article-title>Sleep and EEG Power Spectral Analysis in Three Transgenic Mouse Models of Alzheimer’s Disease: APP/PS1, 3xTgAD, and Tg2576</article-title><source>J Alzheimers Dis</source><year>2018</year><volume>64</volume><fpage>1325</fpage><lpage>1336</lpage><pub-id pub-id-type="doi">10.3233/JAD-180260</pub-id><pub-id pub-id-type="pmcid">PMC6176720</pub-id><pub-id pub-id-type="pmid">29991134</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azami</surname><given-names>H</given-names></name><etal/></person-group><article-title>Beta to theta power ratio in EEG periodic components as a potential biomarker in mild cognitive impairment and Alzheimer’s dementia</article-title><source>Alzheimers Res Ther</source><year>2023</year><volume>15</volume><fpage>133</fpage><pub-id pub-id-type="doi">10.1186/s13195-023-01280-z</pub-id><pub-id pub-id-type="pmcid">PMC10405483</pub-id><pub-id pub-id-type="pmid">37550778</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>W</given-names></name><etal/></person-group><article-title>Neural Oscillation Disorder in the Hippocampal CA1 Region of Different Alzheimer’s Disease Mice</article-title><source>Curr Alzheimer Res</source><year>2023</year><volume>20</volume><fpage>350</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.2174/1567205020666230808122643</pub-id><pub-id pub-id-type="pmcid">PMC10661967</pub-id><pub-id pub-id-type="pmid">37559542</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Multiple cross-frequency coupling analysis of resting-state EEG in patients with mild cognitive impairment and Alzheimer’s disease</article-title><source>Front Aging Neurosci</source><year>2023</year><volume>15</volume><elocation-id>1142085</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2023.1142085</pub-id><pub-id pub-id-type="pmcid">PMC10436577</pub-id><pub-id pub-id-type="pmid">37600515</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheijbeler</surname><given-names>EP</given-names></name><name><surname>de Haan</surname><given-names>W</given-names></name><name><surname>Stam</surname><given-names>CJ</given-names></name><name><surname>Twisk</surname><given-names>JWR</given-names></name><name><surname>Gouw</surname><given-names>AA</given-names></name></person-group><article-title>Longitudinal resting-state EEG in amyloid-positive patients along the Alzheimer’s disease continuum: considerations for clinical trials</article-title><source>Alzheimers Res Ther</source><year>2023</year><volume>15</volume><fpage>182</fpage><pub-id pub-id-type="doi">10.1186/s13195-023-01327-1</pub-id><pub-id pub-id-type="pmcid">PMC10585755</pub-id><pub-id pub-id-type="pmid">37858173</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopcanova</surname><given-names>M</given-names></name><etal/></person-group><article-title>Resting-state EEG signatures of Alzheimer’s disease are driven by periodic but not aperiodic changes</article-title><source>Neurobiol Dis</source><year>2024</year><volume>190</volume><elocation-id>106380</elocation-id><pub-id pub-id-type="pmid">38114048</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Early-stage dysfunction of hippocampal theta and gamma oscillations and its modulation of neural network in a transgenic 5xFAD mouse model</article-title><source>Neurobiol Aging</source><year>2020</year><volume>94</volume><fpage>121</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">32619873</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altunkaya</surname><given-names>A</given-names></name><etal/></person-group><article-title>Altered sleep behavior strengthens face validity in the ArcAbeta mouse model for Alzheimer’s disease</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><elocation-id>951</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-51560-3</pub-id><pub-id pub-id-type="pmcid">PMC10781983</pub-id><pub-id pub-id-type="pmid">38200079</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>AKF</given-names></name><etal/></person-group><article-title>EEG slowing during REM sleep in older adults with subjective cognitive impairment and mild cognitive impairment</article-title><source>Sleep</source><year>2024</year><pub-id pub-id-type="doi">10.1093/sleep/zsae051</pub-id><pub-id pub-id-type="pmcid">PMC11168761</pub-id><pub-id pub-id-type="pmid">38394454</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petit</surname><given-names>D</given-names></name><name><surname>Montplaisir</surname><given-names>J</given-names></name><name><surname>Lorrain</surname><given-names>D</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name></person-group><article-title>Spectral analysis of the rapid eye movement sleep electroencephalogram in right and left temporal regions: a biological marker of Alzheimer’s disease</article-title><source>Ann Neurol</source><year>1992</year><volume>32</volume><fpage>172</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1510357</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petit</surname><given-names>D</given-names></name><name><surname>Lorrain</surname><given-names>D</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Montplaisir</surname><given-names>J</given-names></name></person-group><article-title>Regional spectral analysis of the REM sleep EEG in mild to moderate Alzheimer’s disease</article-title><source>Neurobiol Aging</source><year>1993</year><volume>14</volume><fpage>141</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8487916</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brayet</surname><given-names>P</given-names></name><etal/></person-group><article-title>Quantitative EEG of Rapid-Eye-Movement Sleep: A Marker of Amnestic Mild Cognitive Impairment</article-title><source>Clin EEG Neurosci</source><year>2016</year><volume>47</volume><fpage>134</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">26323578</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Atri</surname><given-names>A</given-names></name><etal/></person-group><article-title>EEG alterations during wake and sleep in mild cognitive impairment and Alzheimer’s disease</article-title><source>iScience</source><year>2021</year><volume>24</volume><elocation-id>102386</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2021.102386</pub-id><pub-id pub-id-type="pmcid">PMC8086022</pub-id><pub-id pub-id-type="pmid">33981973</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Rozario</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Objective measurement of sleep in mild cognitive impairment: A systematic review and meta-analysis</article-title><source>Sleep Med Rev</source><year>2020</year><volume>52</volume><elocation-id>101308</elocation-id><pub-id pub-id-type="pmid">32302775</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanclares</surname><given-names>C</given-names></name><etal/></person-group><article-title>Beyond the brain: early autonomic dysfunction in Alzheimer’s disease</article-title><source>Acta Neuropathol Commun</source><year>2025</year><volume>13</volume><fpage>128</fpage><pub-id pub-id-type="doi">10.1186/s40478-025-02042-8</pub-id><pub-id pub-id-type="pmcid">PMC12150586</pub-id><pub-id pub-id-type="pmid">40495232</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mineur</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>3573</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1073/pnas.1219731110</pub-id><pub-id pub-id-type="pmcid">PMC3587265</pub-id><pub-id pub-id-type="pmid">23401542</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Inhibiting medial septal cholinergic neurons with DREADD alleviated anxiety-like behaviors in mice</article-title><source>Neurosci Lett</source><year>2017</year><volume>638</volume><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">27939976</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>L</given-names></name><etal/></person-group><article-title>Acetylcholine Muscarinic Receptors in Ventral Hippocampus Modulate Stress-Induced Anxiety-Like Behaviors in Mice</article-title><source>Front Mol Neurosci</source><year>2020</year><volume>13</volume><elocation-id>598811</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2020.598811</pub-id><pub-id pub-id-type="pmcid">PMC7769836</pub-id><pub-id pub-id-type="pmid">33384583</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Distinct septo-hippocampal cholinergic projections separately mediate stress-induced emotional and cognitive deficits</article-title><source>Sci Adv</source><year>2024</year><volume>10</volume><elocation-id>eado1508</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.ado1508</pub-id><pub-id pub-id-type="pmcid">PMC11546849</pub-id><pub-id pub-id-type="pmid">39514666</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name></person-group><article-title>Cholinergic regulation of object recognition memory</article-title><source>Front Behav Neurosci</source><year>2022</year><volume>16</volume><elocation-id>996089</elocation-id><pub-id pub-id-type="doi">10.3389/fnbeh.2022.996089</pub-id><pub-id pub-id-type="pmcid">PMC9557046</pub-id><pub-id pub-id-type="pmid">36248033</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solari</surname><given-names>N</given-names></name><name><surname>Hangya</surname><given-names>B</given-names></name></person-group><article-title>Cholinergic modulation of spatial learning, memory and navigation</article-title><source>Eur J Neurosci</source><year>2018</year><volume>48</volume><fpage>2199</fpage><lpage>2230</lpage><pub-id pub-id-type="doi">10.1111/ejn.14089</pub-id><pub-id pub-id-type="pmcid">PMC6174978</pub-id><pub-id pub-id-type="pmid">30055067</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shivakumar</surname><given-names>AB</given-names></name><name><surname>Mehak</surname><given-names>SF</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Gangadharan</surname><given-names>G</given-names></name></person-group><article-title>Medial septal cholinergic neurotransmission is essential for social memory in mice</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2025</year><volume>136</volume><elocation-id>111207</elocation-id><pub-id pub-id-type="pmid">39615870</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimpinella</surname><given-names>D</given-names></name><etal/></person-group><article-title>Septal cholinergic input to CA2 hippocampal region controls social novelty discrimination via nicotinic receptor-mediated disinhibition</article-title><source>Elife</source><year>2021</year><volume>10</volume><pub-id pub-id-type="doi">10.7554/eLife.65580</pub-id><pub-id pub-id-type="pmcid">PMC8547952</pub-id><pub-id pub-id-type="pmid">34696824</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>JA</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name></person-group><article-title>Neurobehavioral and neuropsychiatric symptoms in Alzheimer’s disease: characteristics and treatment</article-title><source>Neurol Clin</source><year>2000</year><volume>18</volume><fpage>829</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">11072263</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellio</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Perinatal choline supplementation prevents learning and memory deficits and reduces brain amyloid Abeta42 deposition in AppNL-G-F Alzheimer’s disease model mice</article-title><source>PLoS One</source><year>2024</year><volume>19</volume><elocation-id>e0297289</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0297289</pub-id><pub-id pub-id-type="pmcid">PMC10843108</pub-id><pub-id pub-id-type="pmid">38315685</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavedo</surname><given-names>E</given-names></name><etal/></person-group><article-title>Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><elocation-id>11706</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-09780-3</pub-id><pub-id pub-id-type="pmcid">PMC5601919</pub-id><pub-id pub-id-type="pmid">28916821</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis</article-title><source>Cell Metab</source><year>2011</year><volume>13</volume><fpage>195</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2011.01.010</pub-id><pub-id pub-id-type="pmcid">PMC3033043</pub-id><pub-id pub-id-type="pmid">21284986</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>CF</given-names></name><etal/></person-group><article-title>Sexually dimorphic neurons in the ventromedial hypothalamus govern mating in both sexes and aggression in males</article-title><source>Cell</source><year>2013</year><volume>153</volume><fpage>896</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.04.017</pub-id><pub-id pub-id-type="pmcid">PMC3767768</pub-id><pub-id pub-id-type="pmid">23663785</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><etal/></person-group><article-title>GABA and glutamate neurons in the VTA regulate sleep and wakefulness</article-title><source>Nat Neurosci</source><year>2019</year><volume>22</volume><fpage>106</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1038/s41593-018-0288-9</pub-id><pub-id pub-id-type="pmcid">PMC6390936</pub-id><pub-id pub-id-type="pmid">30559475</pub-id></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klugmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats</article-title><source>Mol Cell Neurosci</source><year>2005</year><volume>28</volume><fpage>347</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">15691715</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anisimov</surname><given-names>VN</given-names></name><etal/></person-group><article-title>Reconstruction of vocal interactions in a group of small songbirds</article-title><source>Nat Methods</source><year>2014</year><volume>11</volume><fpage>1135</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">25262206</pub-id></element-citation></ref><ref id="R101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunaydin</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Natural neural projection dynamics underlying social behavior</article-title><source>Cell</source><year>2014</year><volume>157</volume><fpage>1535</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.05.017</pub-id><pub-id pub-id-type="pmcid">PMC4123133</pub-id><pub-id pub-id-type="pmid">24949967</pub-id></element-citation></ref><ref id="R102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraeuter</surname><given-names>AK</given-names></name><name><surname>Guest</surname><given-names>PC</given-names></name><name><surname>Sarnyai</surname><given-names>Z</given-names></name></person-group><article-title>The Y-Maze for Assessment of Spatial Working and Reference Memory in Mice</article-title><source>Methods Mol Biol</source><year>2019</year><volume>1916</volume><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">30535688</pub-id></element-citation></ref><ref id="R103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leger</surname><given-names>M</given-names></name><etal/></person-group><article-title>Object recognition test in mice</article-title><source>Nat Protoc</source><year>2013</year><volume>8</volume><fpage>2531</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24263092</pub-id></element-citation></ref><ref id="R104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matikainen-Ankney</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Rodent Activity Detector (RAD), an Open Source Device for Measuring Activity in Rodent Home Cages</article-title><source>eNeuro</source><year>2019</year><volume>6</volume><pub-id pub-id-type="doi">10.1523/ENEURO.0160-19.2019</pub-id><pub-id pub-id-type="pmcid">PMC6620392</pub-id><pub-id pub-id-type="pmid">31235468</pub-id></element-citation></ref><ref id="R105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abelson</surname><given-names>KS</given-names></name><name><surname>Kalliokoski</surname><given-names>O</given-names></name><name><surname>Teilmann</surname><given-names>AC</given-names></name><name><surname>Hau</surname><given-names>J</given-names></name></person-group><article-title>Applicability of Commercially Available ELISA Kits for the Quantification of Faecal Immunoreactive Corticosterone Metabolites in Mice</article-title><source>In Vivo</source><year>2016</year><volume>30</volume><fpage>739</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">27815456</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><title><italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice exhibit local and broadcasted Aβ deposits.</title><p><bold>a, Generation of <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice</bold>. Following the injection of <italic>AAV-DIO-App<sup>NL-G-F</sup>-2A-GFP</italic> in the MS of <italic>ChAT-Cre</italic> mice, EEG/EMG recordings were conducted every four months during the year post-injection to monitor sleep-wake cycles. From 12 months onward, behavioral assessments, locomotor activity monitoring, and baseline stress level measurements were performed, followed by brain collection for histological analyses (scale bar: 100 μm).</p><p><bold>b, Extent of histological analysis of the MS</bold>. Coronal brain sections (4-5 sections per animal), spanning from bregma +1.18 mm to +0.26 mm, were selected to encompass the entire rostrocaudal extent of the MS. In plots representing quantified immunohistochemical data of the BF, gradient color-coding indicates the rostrocaudal position of each brain slice from anterior to posterior BF.</p><p><bold>c, Aβ deposition in BF cholinergic areas (MS, VDB, and HDB)</bold>. Coronal brain sections, collected 13-14 post-surgery, of <italic>MS<sup>ChAT</sup>-GFP</italic> (left) and <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> (right) mice showing Aβ detected with antibody D54D2 (red) and cell nuclei indicated with Hoechst staining (blue; scale bar: 200 μm).</p><p><bold>d, Accumulation of Aβ in <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice</bold>. <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice (<italic>n</italic> = 4 males, <italic>n</italic> = 4 females) exhibited significantly greater Aβ accumulation (D54D2-stained area) in the MS (<italic>p</italic> &lt; 0.001), VDB (<italic>p</italic> = 0.0014), and HDB (<italic>p</italic> &lt; 0.001) compared with <italic>MS<sup>ChAT</sup>-GFP</italic> mice (<italic>n</italic> = 4 males, <italic>n</italic> = 4 females). See panel b for gradient color-coding.</p><p><bold>e, Spread of Aβ in the hippocampus of <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice</bold>. Coronal brain sections of the hippocampus show immunostaining for Aβ (D54D2, red) and nuclei (Hoechst, blue) in <italic>MS<sup>ChAT</sup>-GFP</italic> (left) and <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> (right) mice at 13-14 months post-surgery. For each brain region analyzed, 3-5 coronal brain sections (40 μm) were collected per animal (scale bar: 200 μm).</p><p><bold>f, Quantification of deposited Aβ in the projection fields of MS<sup>ChAT</sup> neurons</bold>. <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice (<italic>n</italic> = 3 males, <italic>n</italic> = 4 females) had significantly higher Aβ accumulation in the hippocampus (CA3, CA2, CA1, dentate gyrus, and subiculum; <italic>p</italic> = 0.0065), thalamus (<italic>p</italic> = 0.0462), amygdala (<italic>p</italic> = 0.0284), medial prefrontal cortex (prelimbic and cingulate cortices; <italic>p</italic> = 0.0051), primary sensory cortices (somatosensory, motor, and visual; <italic>p</italic> = 0.0061), and hypothalamus (<italic>p</italic> = 0.0085) relative to <italic>MS<sup>ChAT</sup>-GFP</italic> mice (<italic>n</italic> = 4 males, <italic>n</italic> = 4 females). No significant differences were observed in the medial habenula, olfactory bulb, or entorhinal cortex. See <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1c</xref> for gradient color-coding.</p><p>Statistical analysis: linear mixed-model ANOVA with Holm-Bonferroni correction for multiple pairwise comparisons where appropriate; mean ± SEM. Symbols: ▪ males, • females, ♦ males and females, * <italic>p</italic> &lt; 0.05, ** <italic>p</italic> &lt; 0.01, *** <italic>p</italic> &lt; 0.001. Parts of this figure were created with the help of <ext-link ext-link-type="uri" xlink:href="http://BioRender.com">BioRender.com</ext-link>.</p></caption><graphic xlink:href="EMS207222-f001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><title>Loss of BF cholinergic neurons in aged <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> and in <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice.</title><p><bold>a</bold>, Coronal brain sections show immunostaining of cholinergic neurons (ChAT, orange) and nuclei (Hoechst, blue) in the MS, VDB, and HDB of control <italic>MS<sup>ChAT</sup>-GFP</italic> (control; left) or <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup>(right) 13-14 months after AAV injections (scale bar: 200 μm).</p><p><bold>b</bold>, Cholinergic neuron number in the MS of <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice (<italic>n</italic> = 4 males, <italic>n</italic> = 4 females) was reduced compared with <italic>MS<sup>ChAT</sup>-GFP</italic> mice (<italic>n</italic> = 4 males, <italic>n</italic> = 4 females; <italic>p</italic> &lt; 0.001). There were no significant changes in the VDB or HDB. See <xref ref-type="fig" rid="F1">Fig. 1b</xref> for gradient color-coding.</p><p><bold>c</bold>, Coronal brain sections show immunostaining of cholinergic neurons (ChAT, orange) and nuclei (Hoechst, blue) in the MS, VDB, and HDB of 13-14-month-old <italic>App<sup>WT</sup></italic> (control; left) and <italic>App</italic><sup>NL-G-F/NL-G-F</sup> (right) mice (scale bar: 200 μm).</p><p><bold>d</bold>, Cholinergic neuron number in the MS (<italic>p</italic> = 0.0012) and HDB (<italic>p</italic> &lt; 0.001) of <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice (<italic>n</italic> = 4 males, <italic>n</italic> = 4 females) was reduced relative to <italic>App<sup>WT</sup></italic> counterparts (<italic>n</italic> = 4 males, <italic>n</italic> = 4 females). The VDB remained unaffected. See <xref ref-type="fig" rid="F1">Fig. 1b</xref> for gradient color-coding.</p><p>Statistical analysis: linear mixed-model ANOVA with Holm-Bonferroni correction for multiple pairwise comparisons where appropriate; mean ± SEM. Symbols: ▪ males, • females, ♦ males and females, * <italic>p</italic> &lt; 0.05, ** <italic>p</italic> &lt; 0.01, *** <italic>p</italic> &lt; 0.001.</p></caption><graphic xlink:href="EMS207222-f002"/></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><title>Comparable cognitive and emotional impairments in <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> and <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice.</title><p><bold>a, Home-cage locomotor activity</bold>. Locomotor activity within the home cage was continuously monitored over an average period of 6.8 days. Average activity over 24 h was calculated, and analyses were performed separately for the 12 h light and dark phases. <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice (<italic>n</italic> = 5 males, <italic>n</italic> = 5 females) exhibited significantly increased locomotor activity compared to <italic>MS<sup>ChAT</sup>-GFP</italic> controls (<italic>n</italic> = 5 males, <italic>n</italic> = 5 females) during the light (<italic>p</italic> = 0.0287) and dark (<italic>p</italic> = 0.0129) phases at 13-14 months post-surgery. Similarly, 13-14 month-old <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice (<italic>n</italic> = 5 males, <italic>n</italic> = 7 females) displayed increased locomotor activity relative to <italic>App<sup>WT</sup></italic> controls (<italic>n</italic> = 6 males, <italic>n</italic> = 7 females), but this effect was restricted to the dark period (<italic>p</italic> = 0.0063). Females were more active than males (<italic>p</italic> &lt; 0.001; see Supplementary information for detailed statistics).</p><p><bold>b, Stress levels</bold>. Basal stress levels were assessed by quantifying fecal corticosterone metabolites (FCM) from samples collected across five time windows spanning a 28 h period (indicated by the gray bar). FCM levels in <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice (<italic>n</italic> = 6 males, <italic>n</italic> = 5 females) did not significantly differ <italic>MS<sup>ChAT</sup>-GFP</italic> animals (<italic>n</italic> = 5 males, <italic>n</italic> = 5 females). In contrast, <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice (<italic>n</italic> = 5 males, <italic>n</italic> = 5 females) exhibited significantly elevated FCM levels compared <italic>App<sup>WT</sup></italic> counterparts (<italic>n</italic> = 6 males, <italic>n</italic> = 5 females) at zeitgeber times ZT22 (<italic>p</italic> = 0.0171), ZT6 (<italic>p</italic> = 0.0111), ZT14 (<italic>p</italic> = 0.0024), ZT18 (<italic>p</italic> = 0.0317), and again at ZT22 (<italic>p</italic> = 0.0224). In both models, female mice showed higher FCM levels than males (<italic>p</italic> &lt; 0.001).</p><p><bold>c, Spatial working memory – Y-maze test</bold>. <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice (<italic>n</italic> = 7 males, <italic>n</italic> = 6 females), as well as <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice (<italic>n</italic> = 8 males, <italic>n</italic> = 7 females), exhibited significantly fewer spontaneous alternations compared to <italic>MS<sup>ChAT</sup>-GFP</italic> (<italic>n</italic> = 6 males, <italic>n</italic> = 6 females; <italic>p</italic> &lt; 0.001) and <italic>App<sup>WT</sup></italic> controls (<italic>n</italic> = 6 males, <italic>n</italic> = 6 females; <italic>p</italic> &lt; 0.001), respectively, indicating impaired working memory.</p><p><bold>d, Non-spatial working memory – Novel object recognition task (NORT)</bold>. Twenty-four hours after familiarization with two identical objects (maximum 20 s exploration), mice were exposed to one familiar and one novel object during the test phase. <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice (<italic>n</italic> = 5 males, <italic>n</italic> = 6 females) did not display a significant preference for the novel object, suggesting working memory deficit. In contrast, <italic>MS<sup>ChAT</sup>-GFP</italic> controls (<italic>n</italic> = 5 males, <italic>n</italic> = 6 females) showed a significant preference for the novel object (<italic>p</italic> &lt; 0.001). Both <italic>App</italic><sup>NL-G-F/NL-G-F</sup> (<italic>n</italic> = 6 males, <italic>n</italic> = 7 females) and <italic>App<sup>WT</sup></italic> (<italic>n</italic> = 6 males, <italic>n</italic> = 5 females) mice also demonstrated a significant preference for the novel object (<italic>p</italic> &lt; 0.001).</p><p><bold>e, Anxiety-like behavior – Open field test</bold>. <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice (<italic>n</italic> = 6 males, <italic>n</italic> = 6 females) spent significantly more time in the center compared to <italic>MS<sup>ChAT</sup>-GFP</italic> controls (<italic>n</italic> = 5 males, <italic>n</italic> = 6 females; <italic>p</italic> = 0.0031), reflecting a reduction of anxiety-like behavior. Similarly, <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice (<italic>n</italic> = 7 males, <italic>n</italic> = 7 females) spent more time in the center compared to their <italic>App<sup>WT</sup></italic> counterparts (<italic>n</italic> = 7 males, <italic>n</italic> = 7 females; <italic>p</italic> = 0.0031).</p><p><bold>f, Anxiety-like behavior – Light-dark box test</bold>. <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice (<italic>n</italic> = 6 males, <italic>n</italic> = 6 females) spent significantly more time in the illuminated compartment compared to <italic>MS<sup>ChAT</sup>-GFP</italic> animals (<italic>n</italic> = 5 males, <italic>n</italic> = 7 females; <italic>p</italic> = 0.0161), pointing again to a decrease of anxiety-like behavior. Similarly, <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice (<italic>n</italic> = 7 males, <italic>n</italic> = 6 females) showed increased time in the lit compartment compared to <italic>App<sup>WT</sup></italic> controls (<italic>n</italic> = 7 males, <italic>n</italic> = 5 females; <italic>p</italic> = 0.0146).</p><p>Statistical analysis: linear mixed-model and standard ANOVAs with Holm-Bonferroni correction for multiple pairwise comparisons where appropriate (one-sample Student’s <italic>t</italic>-test for NORT); mean ± SEM. Symbols: ▪ males, • females, ♦ males and females, * <italic>p</italic> &lt; 0.05, ** <italic>p</italic> &lt; 0.01, *** <italic>p</italic> &lt; 0.001. Parts of this figure were created with the help of <ext-link ext-link-type="uri" xlink:href="http://BioRender.com">BioRender.com</ext-link>.</p></caption><graphic xlink:href="EMS207222-f003"/></fig><fig id="F4" position="float"><label>Fig. 4</label><caption><title>Comparable REMS phenotypes in <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> and <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice with aging.</title><p><bold>a, REMS total duration as <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice age</bold>. During the light phase, REMS duration of <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice (<italic>n</italic> = 7-8 males, <italic>n</italic> = 7 females) diverged at both 8 (<italic>p</italic> = 0.0066) and 12 (<italic>p</italic> &lt; 0.001) months post-AAV injection from that of <italic>MS<sup>ChAT</sup>-GFP</italic> controls (<italic>n</italic> = 7-8 males, <italic>n</italic> = 7-8 females). A significant overall reduction in REMS duration was also observed in <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice relative to <italic>MS<sup>ChAT</sup>-GFP</italic> animals during the dark phase (<italic>p</italic> = 0.0024).</p><p><bold>b, REMS bout length as <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice age</bold>. During the light period, <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice displayed a significant increase in REMS bout length compared with <italic>MS<sup>ChAT</sup>-GFP</italic> animals (<italic>p</italic> = 0.0069).</p><p><bold>c, Number of REMS bouts as <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice age</bold>. <italic>MS<sup>ChAT</sup>-GFP</italic> mice exhibited an age-related increase in the number of REMS bouts during the light phase; by contrast, this parameter remained stable in <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice and significantly diverged from controls at 8 (<italic>p</italic> = 0.0038) and 12 (<italic>p</italic> &lt; 0.001) months. A significant difference between <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> and <italic>MS<sup>ChAT</sup>-GFP</italic> mice during the dark period was observed only at 12 months post-injection (<italic>p</italic> = 0.0258).</p><p><bold>d, REMS total duration as <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice age</bold>.. Similar to the <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> model, <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice (<italic>n</italic> = 6-7 males, <italic>n</italic> = 6-7 females) exhibited significantly reduced REMS duration during the light phase at both 8 (<italic>p</italic> = 0.0167) and 12 (<italic>p</italic> = 0.0011) months relative to <italic>App<sup>WT</sup></italic> animals (<italic>n</italic> = 6-7 males, <italic>n</italic> = 6 females).</p><p><bold>e, REMS bout length as <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice age</bold>. At 12 months of age, REMS episodes were significantly longer in <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice compared to <italic>App</italic><sup>WT</sup> controls during the light period (<italic>p</italic> = 0.0127), consistent with findings in the <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> group.</p><p><bold>f, Number of REMS bouts as <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice age</bold>. The number of REMS bouts during the light phase was significantly reduced in <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice relative to <italic>App</italic><sup>WT</sup> controls at 8 (<italic>p</italic> = 0.0095) and 12 (<italic>p</italic> &lt; 0.001) months, with a significant overall reduction also detected during the dark phase (<italic>p</italic> = 0.0456).</p><p><bold>g, Increased EEG delta and decreased theta power of REMS in aged <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice</bold>. Spectral analysis of EEG at 12 months post-AAV injection revealed increased delta power (1-4.4 Hz) in <italic>MS<sup>ChAT</sup>-App</italic><sup>NL-G-F</sup> mice (<italic>n</italic> = 7 males, <italic>n</italic> = 6 females) during both light (<italic>p</italic> = 0.0041) and dark (<italic>p</italic> = 0.0340) phases compared to <italic>MS<sup>ChAT</sup>-GFP</italic> animals (<italic>n</italic> = 7 males, <italic>n</italic> = 7 females), accompanied by a significant reduction in theta power (6-9 Hz) in both periods (light: <italic>p</italic> = 0.0027; dark: <italic>p</italic> = 0.0232).</p><p><bold>h, No changes in EEG power in REMS of aged <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice</bold>. Spectral analysis of EEG in 12-month-old <italic>App</italic><sup>NL-G-F/NL-G-F</sup> mice (<italic>n</italic> = 5 males, <italic>n</italic> = 6 females) did not reveal significant differences from <italic>App</italic><sup>WT</sup> controls (<italic>n</italic> = 6 males, <italic>n</italic> = 6 females).</p><p>Statistical analysis: linear mixed-model and standard ANOVAs with Holm-Bonferroni correction for multiple pairwise comparisons where appropriate; mean ± SEM. Symbols: ▪ males, • females, ♦ males and females, * <italic>p</italic> &lt; 0.05, ** <italic>p</italic> &lt; 0.01, *** <italic>p</italic> &lt; 0.001.</p></caption><graphic xlink:href="EMS207222-f004"/></fig></floats-group></article>